

RESEARCH ARTICLE

A cohort-based study of host gene expression: tumor suppressor and innate immune/inflammatory pathways associated with the HIV reservoir size

Ashok K. Dwivedi^{1‡}, Germán G. Gornalusse^{2,3‡}, David A. Siegel¹, Alton Barbehenn¹, Cassandra Thanh⁴, Rebecca Hoh¹, Kristen S. Hobbs⁴, Tony Pan⁴, Erica A. Gibson⁴, Jeffrey Martin⁵, Frederick Hecht¹, Christopher Pilcher¹, Jeffrey Milush⁴, Michael P. Busch⁶, Mars Stone⁶, Meei-Li Huang^{2,7}, Julieta Reppetti^{3,8}, Phuong M. Vo^{2,3}, Claire N. Levy^{2,3}, Pavitra Roychoudhury^{2,7}, Keith R. Jerome^{2,7}, Florian Hladik^{2,3,9}, Timothy J. Henrich³, Steven G. Deeks^{1‡}, Sulggi A. Lee^{1‡*}



1 Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, California, United States of America, **2** Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America, **3** Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America, **4** Department of Medicine, Division of Experimental Medicine, University of California San Francisco, California, United States of America, **5** Department of Biostatistics & Epidemiology, University of California San Francisco, California, United States of America, **6** Vitalant Blood Bank, San Francisco, California, United States of America, **7** Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, United States of America, **8** Universidad de Buenos Aires (UBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Fisiología y Biofísica Bernardo Houssay (IFIBIO- Houssay), Buenos Aires, Argentina, **9** Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, United States of America

‡ AKD & GGG share first authorship on this work. SGD & SAL share last authorship on this work.
* sulggi.lee@ucsf.edu

OPEN ACCESS

Citation: Dwivedi AK, Gornalusse GG, Siegel DA, Barbehenn A, Thanh C, Hoh R, et al. (2023) A cohort-based study of host gene expression: tumor suppressor and innate immune/inflammatory pathways associated with the HIV reservoir size. *PLoS Pathog* 19(11): e1011114. <https://doi.org/10.1371/journal.ppat.1011114>

Editor: Guido Silvestri, Emory University, UNITED STATES

Received: January 11, 2023

Accepted: November 1, 2023

Published: November 29, 2023

Copyright: © 2023 Dwivedi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Our research sharing plan includes the following data: high throughput quantitative human RNA sequencing, ELISA and plasma cytokine protein results. These data have been de-identified for patient confidentiality and are shared with the broader research community in compliance with NIH policy NOT-OD-03-032. These data are now available in the Dryad data repository at https://datadryad.org/stash/share/JpvuclERLxckKBSjhWODrc0K8GkXh-ayRG3_fP4xZkM The full data citation is: Dwivedi, Ashok

Abstract

The major barrier to an HIV cure is the HIV reservoir: latently-infected cells that persist despite effective antiretroviral therapy (ART). There have been few cohort-based studies evaluating host genomic or transcriptomic predictors of the HIV reservoir. We performed host RNA sequencing and HIV reservoir quantification (total DNA [tDNA], unspliced RNA [usRNA], intact DNA) from peripheral CD4+ T cells from 191 ART-suppressed people with HIV (PWH). After adjusting for nadir CD4+ count, timing of ART initiation, and genetic ancestry, we identified two host genes for which higher expression was significantly associated with smaller total DNA viral reservoir size, *P3H3* and *NBL1*, both known tumor suppressor genes. We then identified 17 host genes for which lower expression was associated with higher residual transcription (HIV usRNA). These included novel associations with membrane channel (*KCNJ2*, *GJB2*), inflammasome (*IL1A*, *CSF3*, *TNFAIP5*, *TNFAIP6*, *TNFAIP9*, *CXCL3*, *CXCL10*), and innate immunity (*TLR7*) genes (FDR-adjusted $q < 0.05$). Gene set enrichment analyses further identified significant associations of HIV usRNA with TLR4/microbial translocation ($q = 0.006$), IL-1/NRLP3 inflammasome ($q = 0.008$), and IL-10 ($q = 0.037$) signaling. Protein validation assays using ELISA and multiplex cytokine assays supported these observed inverse host gene correlations, with P3H3, IL-10, and TNF- α

et al. (Forthcoming 2023). A cohort-based study of host gene expression: tumor suppressor and innate immune/inflammatory pathways associated with the HIV reservoir size [Dataset]. Dryad. <https://doi.org/10.5061/dryad.k3j9kd5dw>.

Funding: This work was supported in part by the National Institutes of Health: K23GM112526 (SAL), the DARE Collaboratory (U19 AI096109; SGD), the Division of Intramural Research of the National Institutes (MC), UM1 AI126623 (KRJ), NIH/NIAID R01A141003 (TJH), and NIH/NCATS KL2TR002317 (GGG). This work was also supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50-RGRL; SGD) and a Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill & Melinda Gates Foundation's Reservoir Assay Validation and Evaluation Network Study Group (RAVEN: INV-008500; MPB). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

protein associations achieving statistical significance ($p < 0.05$). Plasma IL-10 was also significantly inversely associated with HIV DNA ($p = 0.016$). HIV intact DNA was not associated with differential host gene expression, although this may have been due to a large number of undetectable values in our study. To our knowledge, this is the largest host transcriptomic study of the HIV reservoir. Our findings suggest that host gene expression may vary in response to the transcriptionally active reservoir and that changes in cellular proliferation genes may influence the size of the HIV reservoir. These findings add important data to the limited host genetic HIV reservoir studies to date.

Author summary

Although lifelong HIV antiretroviral therapy (ART) suppresses virus, the major barrier to an HIV cure is the persistence of infected cells, “the HIV reservoir.” There are limited host genomic HIV reservoir studies to date. We performed a large cross-sectional study of 191 people with HIV on ART and measured the HIV reservoir size and host gene expression (RNA-seq) from blood CD4+ T cells. We found that individuals with higher expression of host genes involved in suppressing cell proliferation (*P3H3*, *NBL1*) had a smaller total HIV reservoir size. We also observed that individuals with more “transcriptionally active” HIV reservoir had decreased expression of inflammatory signaling (e.g., IL-1 β , TLR7, TNF- α , IL-10) genes as well as two membrane channel proteins (encoded by *KCNJ2*, *GJB2*). While we were able to validate some of these findings at the protein level (*P3H3*, IL-10, TNF- α), further studies are needed to confirm these findings in larger cohorts with longitudinal sampling, including traditionally underrepresented populations in HIV cure research.

Introduction

Despite several unique cases of possible HIV remission [1–3], there is still no HIV vaccine or cure. The major barrier to a cure is the persistence of infected cells during effective antiretroviral therapy (ART). Modern ART has transformed HIV disease into a treatable chronic disease for individuals who have access to, and are able to maintain, viral suppression [4]. However, ART alone does not eliminate persistent virus in most individuals [5,6]. HIV cure trials aimed at reactivating and eliminating the HIV reservoir have thus far failed to show a clinically meaningful reduction in the HIV reservoir [7–12]. There is an urgent need to bridge drug discovery with a deeper understanding of host-viral dynamics. Although several host factors have been shown to influence the size of the “HIV reservoir”, such as the timing of ART initiation after initial HIV infection [13–16], pre-ART viral load [17], ethnicity [17], and sex [17–20], there are few published human genomic and transcriptomic epidemiologic studies describing potential host factors influencing HIV persistence during treated infection.

Prior host genome wide association studies (GWAS) have focused on predictors of viral control (during untreated HIV disease), identifying key mutations in the C-C chemokine receptor type 5 gene (*CCR5 Δ 32*) and the human Major Histocompatibility Complex (MHC) human leukocyte antigen (HLA)-B and -C regions, that influence viral setpoint [21–24]. Recently our group reported these mutations (*CCR5 Δ 32* and *HLA -B*57:01*) are associated with smaller HIV reservoir size [25]. However, mRNA expression from DNA variation is complex and not strictly 1:1 DNA to RNA transcription; gene expression is influenced by various




Fig 1. Study methods. DNA and RNA were extracted from CD4+ T cells enriched from cryopreserved peripheral blood mononuclear cells (PBMCs) from 191 ART-suppressed people with HIV (PWH). Extracted DNA was used to perform HIV reservoir quantification (total DNA by quantitative PCR, intact DNA by digital droplet PCR) and host DNA exome sequencing [37]. Extracted RNA was used to perform HIV reservoir quantification (unspliced RNA by qPCR) and host bulk RNA sequencing for the current study. Created with BioRender.com.

<https://doi.org/10.1371/journal.ppat.1011114.g001>

factors (alternative splicing, polyadenylation, regulatory enhancers, epigenetic changes, etc.) which may differ by cell type and tissue [26–28]. The limited number of host gene expression studies during HIV infection (e.g., RNA sequencing) have compared gene expression between distinct clinical HIV groups. For example, one prior study compared gene expression among HIV “controllers” (individuals able to control virus in the absence of therapy) versus “non-controllers” [29]. Another study compared HIV non-controllers initiating ART “early” (<6 months from HIV infection) versus “later” (≥ 6 months after infection) [30]. However, no epidemiologic study has examined quantitative measures of the HIV reservoir size in relation to differences in host gene expression.

Here, we performed a cross-sectional study of 191 ART-suppressed HIV+ non-controllers to identify differentially expressed host genes in relation to three measures of the peripheral CD4+ T cell reservoir: HIV cell-associated “intact” DNA (an estimate of the frequency of potentially “replication-competent” virus with intact HIV genomes) [31], total DNA (“tDNA,” which approximates the total reservoir size, the sum of intact DNA and defective DNA) and unspliced RNA (“HIV usRNA,” which reflects the “transcriptionally active” reservoir) (Fig 1). *NBL1* and *P3H3*, both encoding for tumor suppressor genes that inhibit cell proliferation, were the only two genes host genes significantly associated with HIV total DNA reservoir size; higher expression of these genes was associated with lower HIV total DNA. HIV usRNA was significantly inversely associated with several host genes involved in innate immune and inflammatory signaling, as well as with two genes encoding for membrane channel proteins involved in HIV-1 entry and cell-cell communication. Protein validation in a subset of participants with additional biospecimen availability demonstrated consistent inverse associations as observed in the RNA-seq for HIV total DNA (*P3H3*) and HIV usRNA (*IL-10* and *TNF- α*). Further studies are needed to validate these findings, ideally with dedicated functional

genomic and intracellular protein assays using longitudinal samples to demonstrate causality of these observed associations. Our findings add important clinical and immunologic data to the limited host genomic HIV reservoir studies to date.

Results

Study population

A total of 191 ART-suppressed participants were selected from the UCSF SCOPE and Options cohorts (S1 Fig). HIV “controllers” [32–34] were excluded (individuals with undetectable viral loads in the absence of therapy for ≥ 1 year). Estimated date of detected infection (EDDI) was calculated to determine recency of infection in relation to ART initiation using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>) [35]. The study included individuals who initiated ART during early (within 6 months) and chronic (>6 months) HIV (Table 1). The median age of the cohort was 47 years, nadir CD4+ T cell count, 352 cells/mm³, pre-ART viral load, 5.1 log₁₀copies/mL, and years of ART suppression, 5.1 years. Consistent with our San Francisco-based study population, participants were mostly male (96%) and reported diverse ethnicity, which was reflected in our principal component analysis (PCA) [36] based on our previously published host DNA exome sequencing data [37] (S2 Fig). PCs generated for each participant were included in all downstream multivariate models to adjust for potential confounding by genetic ancestry.

Measures of the HIV total DNA and unspliced RNA were correlated, but low levels of intact DNA were detected

CD4+ T cells from cryopreserved PBMCs were isolated by magnetic negative selection, and RNA was extracted for HIV reservoir quantification (usRNA) and host transcriptomics (RNA-seq) while DNA was extracted for HIV reservoir quantification (tDNA, intact DNA). Most of the HIV reservoir consists of cells harboring defective virus [38,39], while the “replication-competent” reservoir measures that HIV-infected cells harboring intact DNA, capable of producing infectious virions [31,40,41]. Currently, there is no “gold standard” for measuring the HIV reservoir [42,43]. Here, we measured HIV total DNA (tDNA), which approximates the total defective and intact proviral DNA reservoir, and HIV unspliced RNA (usRNA), which

Table 1. Descriptive statistics for the study population of 191 HIV-infected ART-suppressed non-controllers.

Descriptive Characteristic	Total (N = 191)	Early-Treated ^a (N = 54)	Later-Treated ^a (N = 137)
Male (%) ^b	183 (96%)	54 (100%)	129 (94%)
Age (years)	47 (13)	44 (12)	47 (13)
Nadir CD4+ T cell count (cells/mm ³)	352 (251)	522 (346)	304 (190)
Maximum pre-ART HIV RNA (log ₁₀ copies/mL)	5.1 (0.9)	5.6 (0.7)	5.0 (0.8)
Duration of ART suppression (years)	5.1 (4.2)	6.0 (4.3)	4.7 (4.2)
Timing of ART initiation (years)	2.0 (4.6)	0.20 (0.19)	3.5 (4.3)
HIV intact DNA (log ₁₀ copies/10 ⁶ CD4+ T cells)	1.3 (1.0)	1.3 (0.5)	1.9 (1.0)
HIV total DNA (log ₁₀ copies/10 ⁶ CD4+ T cells)	1.0 (1.3)	0.4 (1.3)	1.2 (1.3)
HIV unspliced RNA (log ₁₀ copies/10 ⁶ CD4+ T cells)	3.2 (0.8)	3.0 (0.8)	3.3 (0.7)
HIV RNA/DNA	2.3 (1.0)	2.4 (1.0)	2.3 (0.9)

^a Early-treated = Individuals who initiated ART within 6 months of the date of detected HIV infection; later-treated = Individuals who initiated ART after 6 months of date of detected HIV infection.

^b Absolute frequencies (with percent or median values).

<https://doi.org/10.1371/journal.ppat.1011114.t001>

estimates the “transcriptionally active” HIV reservoir, using an in-house qPCR TaqMan assay [44]. Using the remaining extracted DNA from the CD4+ T cells, we performed a multiplexed ddPCR assay targeting three regions of the HIV-1 genome to quantify the frequency of cells with “intact” HIV (a proxy for the frequency of replication-competent provirus) [31]. Of the three measures that we performed to quantify the HIV reservoir, HIV total DNA and unspliced RNA were highly correlated with one another (both quantified using quantitative, qPCR), Spearman $R = 0.55$, $p = 1.6 \times 10^{-17}$ (S3 Fig). HIV intact DNA (performed as a separate droplet digital, ddPCR assay using remaining DNA samples) was significantly associated with HIV usRNA (Spearman $R = 0.26$, $p = 5.0 \times 10^{-4}$) but not HIV total DNA. This may have been due to unusually high proportion of our study population with undetectable values (48%) for HIV intact DNA (while HIV total DNA by qPCR was measurable in 95% of samples) as described further in the Discussion section.

Known clinical predictors of the HIV reservoir size were associated with HIV total DNA, unspliced RNA, and intact DNA

Earlier timing of ART initiation and higher nadir CD4+ T cell count were associated with smaller HIV reservoir size in our cohort, consistent with prior reports [17,39,43]. Earlier timing of ART initiation (<6 months from infection) was significantly associated with lower levels of total DNA (Spearman $R = 0.29$; $p = 2.3 \times 10^{-5}$) and usRNA (Spearman $R = 0.28$; $p = 4.2 \times 10^{-5}$) and demonstrated a trend with HIV intact DNA (Spearman $R = 0.14$; $p = 0.061$) (S4 Fig). Lower nadir CD4+ T cell counts were associated with higher total HIV DNA (Spearman $R = -0.26$; $p = 2.3 \times 10^{-4}$), as well as with higher HIV usRNA (Spearman $R = -0.30$; $p = 1.5 \times 10^{-5}$) and HIV intact DNA (Spearman $R = -0.27$; $p = 3.7 \times 10^{-4}$) (S5 Fig). We did not observe a significant association with duration of ART suppression, age, or pre-ART viral load. Given the low frequency of females and transgender participants in our study, we were unable to formally compare results based on sex/gender, but sensitivity analyses suggested that inclusion of these participants did not change our overall findings and thus results are shown for the entire combined cohort.

Individuals with higher expression of tumor suppressor genes (*P3H3*, *NBL1*) had smaller HIV total DNA reservoir size

Peripheral CD4+ T cells isolated by magnetic negative selection were subjected to bulk host mRNA sequencing. Differential gene expression analyses demonstrated that individuals with higher *NBL1* and *P3H3* gene expression had significantly lower HIV total DNA (measured by percent change in host gene expression per two-fold change in HIV total DNA; *NBL1*: -1.8%, $q = 0.012$; *P3H3*: -1.6%, $q = 0.012$) in multivariate models controlling for significant covariates, nadir CD4+ T cell count, timing of ART initiation, genetic ancestry (PCs [36,37]), and residual variability (PEERs [45]) (Table 2). *P3H3* encodes for Prolyl 3-Hydroxylase 3, which plays a key role in collagen biosynthesis, affecting properties of the extracellular matrix [46–49], and has been previously been shown to act as a tumor suppressor in breast, lymphoid, and other cancers [50–52], while *NBL1* encodes for neuroblastoma suppressor of tumorigenicity 1 [53,54], a transcription factor that is involved in the negative regulation of cell cycle (G1/S transition) [55–58]. The overall expression for these genes was low but were consistent with population mean normalized gene expression from the Human Cell Atlas [59]. Analyzing *NBL1* and *P3H3* gene expression in transcripts per million (TPM), in addition to analyzing these as normalized gene counts (standard protocol for bulk RNA-seq analyses which include filtering steps to remove low-expressed genes [60–62]), yielded similar results (*NBL1*: average TPM 3.37, Spearman $R = -0.21$, $p = 0.0029$; *P3H3*, average TPM = 2.10, Spearman $R = -0.31$,

Table 2. Differentially expressed host genes in relation to HIV total DNA. Results shown for the overall cohort of 191 participants using a Benjamini-Hochberg false discovery rate (FDR) cutoff value of $q < 0.05$.

HIV Total DNA							
Gene	Gene Name	p ^a	q ^b	FC ^c	% Change ^d	TPM ^e	Description
Total Study Population							
<i>NBL1</i>	NBL1, DAN Family BMP Antagonist	6.14E-07	0.012	0.982	-1.8	3.37	NBL1, also known as neuroblastoma suppressor of tumorigenicity 1, is a transcription factor that belongs to the DAN (differential screening-selected gene aberrant in neuroblastoma) family of proteins [53, 54] and is involved in the negative regulation of cell cycle (G1/S transition) [55–58]. In a recent <i>ex vivo</i> analysis of CD4+ T cells from rhesus macaques after HIV-1 Env immunization and antibody co-administration, <i>NBL1</i> was identified as a host gene that was differentially expressed in all treated (CTLA-4, PD-1, and CTLA-4 + PD-1 Ab) versus control groups [106].
<i>P3H3</i>	Prolyl 3-Hydroxylase 3	1.25E-06	0.012	0.984	-1.6	2.10	<i>P3H3</i> encodes for Prolyl 3-Hydroxylase 3, which functions as a collagen prolyl hydroxylase (vital for collagen biosynthesis) that affects properties of the extracellular matrix and alters cellular behavior [46–49]. Prior studies suggest that <i>P3H3</i> plays a role as a tumor suppressor in breast, lymphoid, and other cancers [50–52].

^a p = two sided p-value.

^b q = two-sided false discovery rate (FDR) Benjamini-Hochberg q-value.

^c FC = fold-change in host gene expression per two-fold change in copies of HIV from multivariate model adjusted for age, sex, nadir CD4+ T cell count, timing of ART initiation, ancestry (PCs), and residual variability (probabilistic estimation of expression residuals, PEERs). Bold font denotes genes with $q < 0.05$.

^d % Change = percent change in host gene expression per two-fold change in copies of HIV.

^e Mean transcripts per million.

<https://doi.org/10.1371/journal.ppat.1011114.t002>

$p = 1.5 \times 10^{-5}$). We also performed unbiased gene set enrichment analyses (GSEA) across the transcriptome using rank-ordered genes by q-value and determining normalized enrichment scores (S1 Table). HIV total DNA was statistically significantly associated with pathways involving complement activation and humoral immune response (e.g., “regulation of complement activation”, $q = 9.8 \times 10^{-6}$; “humoral immune response mediated by circulating immunoglobulin”, $q = 1.6 \times 10^{-5}$; “B cell mediated immunity”, $q = 0.002$; “Fc-gamma receptor signaling pathway”, $q = 0.020$), but these associations were only observed within the European ancestry subgroup.

For a subset of 40 participants for whom we had remaining PBMC aliquots, we were able to perform protein validation of *P3H3* and *NBL1* associations with HIV total DNA (Fig 2). Both genes encode for intracellular proteins [63,64] and thus, we performed CD4+ T cell isolation followed by ELISA (enzyme-linked immunoassay). *P3H3* protein expression levels from peripheral CD4+ T cells demonstrated a significant correlation with HIV total DNA (Spearman $R = -0.44$, $p = 0.0043$) (Fig 2B), consistent with the RNA-seq observations. Similarly, *NBL1* also demonstrated a non-significant inverse trend with HIV total DNA (Spearman $R = -0.29$, $p = 0.073$) (Fig 2D), consistent with the RNA-seq results. Overall, RNA and protein expression levels were positively correlated, but in this small sample, did not meet statistical significance (*P3H3*: Spearman $R = 0.29$, $p = 0.067$; *NBL1*: Spearman $R = 0.22$, $p = 0.17$) (S6 Fig). The inverse associations between protein expression and HIV total DNA were still observed in multivariate models controlling for significant covariates, timing of ART initiation and nadir CD4+ T cell count, but did not meet statistical significance at $p < 0.05$; for each two-fold change in HIV total DNA, there was a -1.2% change in *NBL1* protein expression, $p = 0.060$ (S2 Table). Both *NBL1* and *P3H3* are intracellularly expressed proteins, and protein levels may vary by tissue (e.g., *NBL1* is primarily expressed in the central nervous system [63,64]). In our small sample size, we were only able to test whether the RNA-seq findings validated at the protein level from peripheral CD4+ T cells.




Fig 2. Intracellular P3H3 and NBL1 protein levels from peripheral CD4+ T cells. The distribution of normalized protein levels for P3H3 (A) and NBL1 (C) among a subset of 40 study participants. Correlation scatterplots are shown for P3H3 (B) and NBL1 (D), excluding outliers (>2 standard deviations).

<https://doi.org/10.1371/journal.ppat.1011114.g002>

Individuals with higher HIV unspliced RNA had lower expression of host genes involved in innate immunity, inflammasome activation, and inflammation

HIV unspliced RNA was significantly associated with differential expression of several host genes involved in innate immunity, inflammasome activation, and inflammation. In contrast

to HIV total DNA, which measures the total reservoir size, HIV RNA roughly estimates the “transcriptionally active” HIV reservoir [65,66], which among the participants with measurable HIV intact DNA (S3 Fig), was significantly correlated with usRNA. A total of 17 host genes, the majority of which reflect inflammatory pathways, were significantly lower among individuals with higher HIV usRNA, including after adjustment for significant covariates, timing of ART initiation, nadir CD4+ T cell count, genetic ancestry (PCs), and residual variability (PEERs) (Table 3). Specifically, there was approximately a 5–10% decrease in the expression of these host genes for each two-fold increase in HIV usRNA, based on our multivariate model estimates. Host genes associated with HIV usRNA represented inflammasome activation and tumor necrosis factor (*IL1A*: -9.6%, $q = 0.012$, *CSF3*: -7.5%, $q = 0.013$; *TNFAIP6*: -7.6%, $q = 0.016$, *TNFAIP9*: -6.9%, $q = 0.031$, *TNFAIP5*: -5.9%, $q = 0.043$), innate immunity (*TLR7*: -7.1%, $q = 0.016$), and chemokine (*CXCL3*: -7.2%, $q = 0.043$; *CXCL10*: -9.2%, $q = 0.049$) signaling genes (Tables 3 and S3). The overall expression of these genes in our cohort was low (Tables 3 and S3) but overall consistent with average normalized population gene expression reported in the Human Cell Atlas [59].

Pathway-based analyses further identified gene sets involving NLRP3 inflammasome, TLR4/microbial sensing, TNF- α , and IL-10 signaling that were associated with HIV usRNA

Given the large number of genes associated with HIV usRNA, we also performed network analyses to interpret clusters of pathways from the gene expression data. We applied the ClueGo network analysis application to visualize the ranked genes ($q < 0.25$) into biologically interpretable clusters [67]. Several key pathways involving inflammasome activation [68–71] and bacterial translocation [72–74] genes were strongly associated with HIV usRNA. These include gene sets involving NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome/IL-1 β signaling, as well as pathways involving microbial translocation, such as toll-like receptor 4, lipopolysaccharide (LPS), and IL-17 signaling (Fig 3). We also used unbiased gene set enrichment analyses (GSEA) using rank-ordered genes in the entire transcriptome to further identify biologically relevant clusters of genes associated with HIV usRNA. Pathways reflecting microbial translocation (“Response to Bacterium”, $q = 7.5 \times 10^{-5}$; “Cellular Response to Lipopolysaccharide”, $q = 0.006$), IL-1 signaling (“Interleukin-1 beta production”, $q = 0.008$; “Regulation of Interleukin-1 Production”, $q = 0.008$), and cytokine production (“Tumor Necrosis Factor Production”, $q = 0.006$; “Tumor Necrosis Factor Superfamily Cytokine Production”, $q = 0.006$; “Regulation of Tumor Necrosis Factor Production”, $q = 0.008$) were again associated with HIV usRNA. In addition, several gene sets related to IL-10 signaling (“regulation of interleukin-10 production”, $q = 0.037$, “Interleukin-10 production”, $q = 0.041$), a pleiotropic cytokine associated HIV immune dysregulation and persistence [75–77], were also significantly associated with HIV usRNA ($q = 0.04$) (Fig 4, S4 Table).

Since several of the host genes and gene sets associated with HIV usRNA reflected cytokine signaling (Tables 3 and S3, Figs 3 and 4), we obtained matched cryopreserved plasma samples from 175 of the 191 participants and designed a series of high-sensitivity multiplex cytokine protein assays (Meso Scale Diagnostics and LSBio). We were able to design assays for eight proteins: IL-1 α , IL-1 β , IL-10, TNF- α , G-CSF, IP-10, TNFAIP5, and sTLR4. Unfortunately, we were unable to perform protein validation of IL-1 α since plasma levels were undetectable in most of our samples, potentially due to this cytokine’s primarily intracellular expression, mostly from monocytes/macrophages [78–81]. Overall, for the 7 genes, the RNA and protein expression levels were positively correlated, and were statistically significant for IL-10, TNF- α , and IL-1 β (IL-10: Spearman $R = 0.34$, $p = 4.3 \times 10^{-6}$; TNF- α : Spearman $R = 0.19$, $p = 0.011$; IL-

Table 3. Differentially expressed host genes in relation to \log_{10} copies of HIV unspliced RNA (usRNA). Results shown for the overall cohort of 191 participants (top panel) as well as the European ancestry subgroup (bottom panel) using a Benjamini-Hochberg false discovery rate (FDR) cutoff value of $q < 0.05$. Additional genes meeting an FDR cut-off of $q < 0.25$ are shown in [S3 Table](#).

Gene	Gene Name	HIV Unspliced RNA				TPM ^e	Description
		p ^a	q ^b	FC ^c	% Change ^d		
Full Cohort							
<i>KCNJ2</i>	Potassium Inwardly Rectifying Channel Subfamily J Member 2, kir2.1	1.49E-07	0.003	0.903	-9.7	2.06	<i>KCNJ2</i> , encodes for an inwardly rectifying potassium channel (Kir2.1). Inwardly rectifying potassium ion channels can regulate HIV-1 entry and release into host cells [82]. Tight regulation of potassium ion concentrations has been shown to play a critical role in HIV-1 virus production in CD4+ T cells in cell culture models [170]. HIV Nef protein has been shown to increase K+ concentrations in cells [171], and in turn, changes in K+ concentration have been shown to regulate stages in the HIV life cycle (viral entry, replication, and release) [82].
<i>IL1A</i>	Interleukin-1 alpha	1.55E-06	0.012	0.904	-9.6	5.81	IL-1 α is one of 11 members of the IL-1 family of cytokines [189]. The IL-1 cytokine family that as damage-associated molecular patterns (DAMPs) triggering innate inflammation and also play a key role in angiogenesis, along with tumor necrosis factor and IL-6 [190]. IL-1 β is the most widely studied member of the IL-1 family of cytokines and is the primary circulating form of IL-1. IL-1 is an “upstream” pro-inflammatory inducer of interleukin-6 (IL-6) [83], which strongly predicts morbidity (e.g., myocardial infarction, stroke, malignancy) [84–87] and mortality [80,86–89] among people living with HIV on ART. The IL-1 signaling pathway, and in particular, IL-1 β , has emerged as a major target for immune modulation [107,159].
<i>GJB2</i>	Gap Junction Protein Beta 2	2.26E-06	0.012	0.929	-7.1	0.68	<i>GJB2</i> , also known as CX26, encodes for gap junction beta 2 protein (connexin 26). Gap junction proteins, or connexins, act as cell-cell communication channels to transport signaling molecules (e.g., K ⁺ , Ca ⁺ , ATP) [83,84], but HIV-1 has been shown to exploit these communication channels to disseminate infection as well as associated inflammation even in the absence of viral replication [85,86]. Connexins are expressed in the endoplasmic reticulum and transported to the plasma membrane as connexin hemichannels that then fuse apposing cells, forming gap junctions [191,192]. A growing body of literature strongly suggests that connexins intensify inflammation by facilitating damage-associated molecular pattern (DAMP) release, which then bind to pattern recognition receptors such as toll-like receptors (TLRs) and nod-like receptors (NLRs). Thus, in several inflammatory diseases, blocking connexin channels has consistently been shown to reduce tissue injury and improve organ function [172].
<i>KCNJ2-AS1</i>	KCNJ2 antisense RNA 1	2.49E-06	0.012	0.916	-8.4	5.20	<i>KCNJ2-AS1</i> is a long non-coding RNA (lncRNA) encodes for KCNJ2 antisense RNA 1. Although initially considered “transcriptional noise,” non-coding natural antisense transcripts’ role in regulating gene expression has been increasingly recognized, especially in light of recent advances in next generation sequencing and transcriptome assembly [193,194]. Indeed, sense-antisense pairs can act as fast evolving self-regulatory hubs capable of rewiring and regulatory networks [195].

(Continued)

Table 3. (Continued)

Gene	Gene Name	HIV Unspliced RNA				TPM ^e	Description
		p ^a	q ^b	FC ^c	% Change ^d		
<i>AC034199.1</i>	<i>AC034199.1</i>	2.88E-06	0.012	0.946	-5.4	0.28	Novel transcript: no data found in literature in association with HIV or immune response.
<i>CSF3</i>	Colony Stimulating Factor 3 (G-CSF)	3.93E-06	0.013	0.925	-7.5	8.04	<i>CSF3</i> encodes for granulocyte stimulating factor 3 (G-CSF), a member of the IL-6 superfamily of cytokines [115]. G-CSF is mostly known for its role as a growth factor for neutrophils, promoting the proliferation and survival of neutrophil precursors. However, G-CSF has also been shown to regulate T cell responses via induction of IL-10 secretion [167], leading to inhibition of CD4+ and CD8+ T cell responses and reduction of cytotoxic responses [168]. Indeed, donor treatment of pegylated G-CSF was found to increase IL-10-producing regulatory T cells (Tregs) and enhance transplant tolerance [169], suggesting that G-CSF can directly modify T cell responses via IL-10 [196].
<i>TNFAIP6</i>	Tumor Necrosis Factor alpha induced protein 6	5.99E-06	0.016	0.924	-7.6	1.14	<i>TNFAIP6</i> encodes for pattern recognition receptor, Tumor Necrosis Factor alpha induced protein 6 which functions as an anti-inflammatory protein [197,198], is induced by IL-1 (upon LPS-stimulation) [118,119], and interacts with <i>TNFAIP5</i> [199,200].
<i>TLR7</i>	Toll Like Receptor 7	6.59E-06	0.016	0.929	-7.1	0.60	<i>TLR7</i> encodes for a PRR that senses HIV single-stranded RNA [160,161] and has been associated viral persistence in several human and non-human primate studies [128–130]. TLR7 agonist administration has been associated with delayed viral rebound [128] and reduced viral reservoirs in non-human primate studies [129]. A human clinical trial of the TLR7 agonist GS-9620 recently demonstrated a delay in viral rebound in HIV controllers after cessation of ART (NCT05281510) [130]. <i>TLR7</i> is located on the X chromosome, and host <i>TLR7</i> transcriptional activity has been linked to acute viremia in HIV+ women (linked to type I interferon production) [132] as well as with enhanced innate immune function (i.e., plasmacytoid dendritic cell IFN- α and TNF- α production) [131].
<i>MRAS</i>	Muscle RAS oncogene homolog	1.07E-05	0.024	0.945	-5.5	0.17	<i>MRAS</i> encodes for a protein in the Ras family of small GTPases which functions as signal transducers in cellular processes.
<i>TNFAIP9/STEAP4</i>	Tumor Necrosis Factor alpha induced protein 9	1.53E-05	0.031	0.931	-6.9	0.83	<i>TNFAIP9</i> encodes for pattern recognition receptor, Tumor Necrosis Factor alpha induced protein 9, also known as <i>STEAP4</i> (six transmembrane epithelial antigen of prostate 4). <i>TNFAIP9</i> has been shown to negatively regulate NF- κ B, STAT-3 signaling, and IL-6 production [150,151].
<i>MIR3945HG</i>	MIR3945 Host Gene	2.09E-05	0.038	0.942	-5.8	0.36	<i>MIR3945HG</i> is an interferon stimulated lncRNA.
<i>DAPK1-IT1</i>	DAPK1 Intronic Transcript 1	2.72E-05	0.043	0.950	-5.0	1.11	<i>DAPK1-IT1</i> is a lncRNA transcribed from the death associated protein kinases 1 (DAPK1).
<i>OR2B11</i>	Olfactory Receptor Family 2 Subfamily B Member 11	2.96E-05	0.043	0.939	-6.1	1.04	<i>OR2B11</i> is a member of G-protein-coupled receptors (GPCR) responsible for the recognition and G protein-mediated transduction of odorant signals.

(Continued)

Table 3. (Continued)

Gene	Gene Name	HIV Unspliced RNA				TPM ^e	Description
		p ^a	q ^b	FC ^c	% Change ^d		
<i>CXCL3</i>	C-X-C Motif Chemokine Ligand 3	3.03E-05	0.043	0.928	-7.2	31.06	<i>CXCL3</i> encodes for C-X-C Motif Chemokine Ligand 3, a member of CXC subfamily called cytokine-induced neutrophil chemoattractant (CINCs). <i>CXCL3</i> regulates monocyte migration [201,202], neutrophils chemoattraction [202–204], and angiogenesis [205], and is induced by proinflammatory IL-17 [206,207].
<i>TNFAIP5</i> <i>/PTX3</i> / <i>TSFG14</i>	TNF Alpha-Induced Protein 5 (TNFAIP5), Pentraxin-related protein (PTX3), Tumor Necrosis Factor-Inducible Protein TSG-14 (TSG14).	3.27E-05	0.043	0.941	-5.9	15.37	<i>TNFAIP5</i> encodes for a pattern recognition receptor, TNF- α induced protein 5, also known as pentraxin-related protein (PTX3) or tumor Necrosis Factor-Inducible Gene 14 Protein (TSFG14). TNFAIP5, or PTX3, is induced in response to TNF- α , TLR engagement and IL-1 β signaling and is part of the pentraxin superfamily of proteins, which includes C-reactive protein (CRP) and serum amyloid [208]. TNFAIP5 is a soluble PRR that plays a key role in host antimicrobial innate immune defense but also functions in complement activation and regulating inflammation in response to tissue repair and cancer [209]. Elevated serum levels of PTX have been associated with severity and survival in patients with sepsis [210].
<i>RRN3P4</i>	RRN3 Pseudogene 4	3.97E-05	0.049	0.950	-5.0	0.83	Pseudogene
<i>CXCL10</i>	C-X-C Motif Chemokine Ligand 10	4.21E-05	0.049	0.908	-9.2	5.79	<i>CXCL10</i> encodes for IP-10 (interferon gamma-induced protein 10) which recruits activated Th1 lymphocytes to sites of infection [120–122] and in HIV, signals through TLR7/9-dependent pathways [122], predicts HIV disease progression [123,124], correlates with acute HIV seroconversion [125], and promotes HIV latency [126,127].
European Ancestry Subpopulation							
<i>TLR7^f</i>	Toll Like Receptor 7	1.48E-06	0.018	0.906	-9.4	0.60	<i>TLR7</i> encodes for a PRR that senses HIV single-stranded RNA [160,161] and has been associated viral persistence in several human and non-human primate studies [128–130].
<i>GJB2^f</i>	Gap Junction Protein Beta 2	2.70E-06	0.018	0.909	-9.1	0.68	<i>GJB2</i> , also known as <i>CX26</i> , encodes for gap junction beta 2 protein (connexin 26). Gap junction proteins, or connexins, act as cell-cell communication channels to transport signaling molecules (e.g., K ⁺ , Ca ⁺ , ATP) [83,84], but HIV-1 has been shown to exploit these communication channels to disseminate infection as well as associated inflammation even in the absence of viral replication [85, 86]. Connexins are expressed in the endoplasmic reticulum and transported to the plasma membrane as connexin hemichannels that then fuse apposing cells, forming gap junctions [191,192]. A growing body of literature strongly suggests that connexins intensify inflammation by facilitating damage-associated molecular pattern (DAMP) release, which then bind to pattern recognition receptors such as toll-like receptors (TLRs) and nod-like receptors (NLRs). Thus, in several inflammatory diseases, blocking connexin channels has consistently been shown to reduce tissue injury and improve organ function [172].
<i>AC034199.1^f</i>	Ac034199.1	3.09E-06	0.018	0.930	-7.0	0.28	novel transcript

(Continued)

Table 3. (Continued)

HIV Unspliced RNA							
Gene	Gene Name	p ^a	q ^b	FC ^c	% Change ^d	TPM ^e	Description
<i>PPP1R17</i>	Protein Phosphatase 1 Regulatory Subunit 17	4.20E-06	0.018	0.934	-6.6	0.09	PPP1R17 (Protein Phosphatase 1 Regulatory Subunit 17) is a substrate for cGMP-dependent protein kinase.
<i>IGSF6</i>	Immunoglobulin Superfamily Member 6	4.73E-06	0.018	0.972	-2.8	2.91	Immunoglobulin superfamily member 6 (IGSF6) is also known as downregulated by activation (DORA).
<i>AL133163.2</i>	AL133163.2	7.81E-06	0.025	0.945	-5.5	0.33	novel transcript

^a p = two sided p-value.

^b q = two-sided false discovery rate (FDR) Benjamini-Hochberg q-value.

^c FC = fold-change in host gene expression per two-fold change in copies of HIV from multivariate model adjusted for age, sex, nadir CD4+ T cell count, timing of ART initiation, ancestry (PCs), and residual variability (probabilistic estimation of expression residuals, PEERs).

^d % Change = percent change in host gene expression per two-fold change in copies of HIV.

^e Mean transcripts per million.

^f % also significant in full cohort analysis.

<https://doi.org/10.1371/journal.ppat.1011114.t003>




Fig 3. Clustering of top differentially expressed host genes associated with HIV unspliced RNA. Given the large number of statistically significant host genes (Tables 3 and S3 Table), we used network analysis to group the top-ranked genes ($q < 0.25$) into biologically interpretable clusters (ClueGo Network software). Host genes related to NLRP3 inflammasome activation (e.g., IL-1 β), Th2 cell cytokine production (e.g., IL-10), and bacterial translocation (e.g., TLR4, lipopolysaccharide) signaling were significantly associated with HIV usRNA. A Benjamini-Hochberg false discovery rate (FDR) of $q < 0.05$ was used to generate nodes (circles) based on kappa scores ≥ 0.4 . The size of the nodes reflects the enrichment significance of the terms, and the different colors represent distinct functional groups. Created with <https://apps.cytoscape.org/apps/cluego>.

<https://doi.org/10.1371/journal.ppat.1011114.g003>




Fig 4. Unbiased gene set enrichment analyses (GSEA) of the entire transcriptome (rank-ordered by q-value) in association with HIV unspliced RNA. Host gene sets involving interferon, IL-10, TNF, NLRP3 inflammasome activation (e.g., IL-1 β , IL-6), and bacterial translocation (e.g., lipopolysaccharide-mediated) signaling were significantly associated with HIV usRNA. A Benjamini-Hochberg false discovery rate (FDR) of $q < 0.05$ was used to generate nodes (circles) based on kappa scores ≥ 0.4 . The size of the nodes reflects the enrichment significance of the terms, and the different colors represent distinct functional groups. Created with <https://apps.cytoscape.org/apps/cluego>.

<https://doi.org/10.1371/journal.ppat.1011114.g004>

1 β : Spearman $R = 0.29$, $p = 1.9 \times 10^{-4}$) (S7 Fig). Of the final set of 7 plasma cytokines assayed, two cytokines, IL-10 and TNF- α , were significantly correlated with HIV usRNA (IL-10: Spearman $R = -0.17$, $p = 0.025$; TNF- α : Spearman $R = -0.23$, $p = 0.0018$) (Fig 5), although these associations did not meet statistical significance in multivariate linear models adjusted for significant covariates (S5 Table). Of note, plasma IL-10 was also significantly inversely correlated with HIV total DNA (Spearman $R = -0.18$, $p = 0.016$) (S8 Fig), even though the *IL10* gene did not meet FDR-adjusted statistical significance in the RNA-seq analysis with HIV DNA per se (S2 Table).

Individuals with higher HIV unspliced RNA had lower expression of host genes encoding membrane channels involved in HIV-1 entry (*KCNJ2*) and cell-cell communication (*GJB2*)

HIV usRNA was also inversely associated with two genes, *KCNJ2* (-9.7%, $q = 0.003$) and *GJB2* (-7.1%, $q = 0.012$), encoding for membrane channel proteins, Kir2.1 and connexin 26, respectively (Table 3). *KCNJ2* encodes for an inwardly rectifying potassium channel, a class of channels that have been shown to regulate HIV-1 entry and release [82], and *GJB2*, or *CX26*, encodes for gap junction beta 2 protein (also known as connexin 26). Gap junctions act as critical cell-cell communication channels for transport signaling molecules and performing physiologic functions, but are often closed or downregulated under pathologic conditions [83,84]. HIV-1 has been shown to exploit these communication channels to disseminate infection as well as associated inflammation even in the absence of viral replication [85,86]. Of note,




Fig 5. Plasma cytokine expression of IL-10 (A), TNF- α (B), IL-1 β (C), G-CSF (D), IP-10 (E), TNFAIP5 (F), and sTLR4 (G). The association between plasma protein expression among 175 study participants in relation to measures of HIV unspliced RNA.

<https://doi.org/10.1371/journal.ppat.1011114.g005>

KCNJ2-AS1, the antisense long non-coding RNA transcript for *KCNJ2*, was also statistically significantly associated with HIV usRNA (-8.4%, $q = 0.012$) (Table 3). Since both *KCNJ2* and *GJB2* encode for membrane-associated proteins [63,64], we performed protein validation from CD4+ T cell isolates for whom we had remaining PBMCs (as we had done above for intracellular protein validation of P3H3 and NBL1). For both genes, RNA and protein expression levels were positively correlated, and the correlation was statistically significant for *GJB2*/connexin




Fig 6. Intracellular Kir2.1 (*KCNJ2*) and connexin 26 (*GJB2*) protein levels from peripheral CD4+ T cells. The distribution of normalized protein levels for Kir2.1 (A) and connexin 26 (C) among a subset of 40 study participants. Correlation scatterplots are shown for Kir2.1 (B) and connexin 26 (D), excluding outliers (>2 standard deviations).

<https://doi.org/10.1371/journal.ppat.1011114.g006>

26 (Spearman $R = 0.37$, $p = 0.02$) (S9 Fig), but we did not observe significant correlations with these proteins as observed in our RNA-seq analyses when testing peripheral CD4+ T cells from a small subset of 40 participants in our cohort (Fig 6, S6 Table).

HIV intact DNA was not significantly associated with host gene expression, but assessment of this may have been limited by a large proportion of undetectable values

HIV intact DNA was undetectable in nearly half (48%) of our measured samples (S3B and S3C Fig), which may have decreased statistical power to detect differentially expressed genes in relation to HIV intact DNA. As previously described, we employed a conservative approach of assigning a zero value for HIV intact DNA if one of two HIV-1 target assay results were undetectable [31,87], since even one target with defective proviral sequence suggests non-intact HIV DNA. Nonetheless, the frequency of undetectable values in our cohort is considerably higher than prior reports using similar (2 or more target) HIV intact DNA assays [88–96]. In contrast, HIV total DNA results using a different assay (qPCR) was measurable in 95% of samples from our cohort (S3A and S3C Fig), suggesting a potential difference due to assay method and/or input sample DNA concentration (HIV intact DNA was performed using remaining extracted DNA after first performing HIV total DNA by qPCR, and there was a general trend demonstrating measurable HIV intact DNA copies with higher concentrations of input sample DNA, S10 Fig). Nonetheless, among participants with measurable HIV intact DNA, differential gene expression analyses demonstrated a slight positive trend ($q < 0.25$) with *PLGLB1* (+6.0%, $q = 0.23$), which encodes for a protein that inhibits thrombus degradation, and *AGL* (+0.9%, $q = 0.23$), which encodes for an enzyme involved in glycogen degradation (S7 Table). Gene set enrichment analyses demonstrated trends with pathways involving neutrophil activation (“Neutrophil Degranulation”, $q = 0.046$; “Neutrophil Activation Involved in Immune Response”, $q = 0.046$; “Leukocyte Activation”; $q = 0.046$), and among the European subgroup, pathways associated with myeloid-mediated immunity (“Myeloid Leukocyte Mediated Immunity”; $q = 0.058$; “Myeloid Cell Activation Involved in Immune Response”; $q = 0.060$) (S8 Table).

Proposed Model of Host Gene Expression and HIV Reservoir from Peripheral CD4+ T Cells

While our cross-sectional study from bulk peripheral CD4+ T cells was unable to demonstrate direct causality, based on the known biologic function(s) of these host genes, we propose a hypothetical feedback loop whereby host genes expressed from uninfected CD4+ T cells act as drivers of the total HIV-infected CD4+ T cell reservoir (Fig 7), and in return, host innate/inflammatory genes from uninfected CD4+ T cells respond to the transcriptionally active HIV-infected CD4+ T cell reservoir (Figs 8 and S11).

Discussion

To our knowledge, this is the largest cohort-based transcriptomic study of host genetic predictors of the HIV reservoir. We observed only two host genes (*P3H3*, *NBL1*) that were significantly (inversely) associated with HIV total DNA, both of which are known tumor suppressor genes and regulate cell cycle. We also observed 17 host genes that were significantly associated with HIV usRNA, all of which demonstrated an inverse relationship with HIV usRNA and are highly interrelated pathways involved in inflammation (e.g., IL-1, IL-6, IL-10, TNF- α , TLR4, NLRP3 inflammasome signaling). We did not observe any host genes that were significantly associated with HIV intact DNA, but this may have been due to a large number of undetectable provirus in our population, potentially due to low sample input DNA concentrations. Protein validation from a subset of participants with remaining biospecimens supported a significant




Fig 7. Proposed model based on host bulk RNA-sequencing and HIV reservoir quantification from peripheral CD4+ T cells of 191 ART-suppressed people with HIV. Increased expression of host tumor suppressor genes *NBL1* and *P3H3* were observed among individuals with smaller HIV total DNA reservoir size in our cross-sectional study ($q < 0.05$). The model depicts host genes from HIV-uninfected cells influencing the subset of CD4+ T cells harboring provirus. Created with [BioRender.com](https://www.biorender.com).

<https://doi.org/10.1371/journal.ppat.1011114.g007>

correlation between HIV total DNA and P3H3 expression (from CD4+ T cells), and between HIV usRNA with plasma IL-10 and TNF- α levels.

Prior HIV integration studies have identified several host oncogenes and/or cell cycle genes that enriched for HIV integrations during long-term ART [97–103]. Tumor suppressor genes




Fig 8. Proposed model for the inverse association between HIV unspliced RNA and host gene expression in our cross-sectional study of 191 ART-suppressed people living with HIV. Within bulk peripheral CD4+ T cells, higher transcriptional reservoir activity (HIV usRNA) from HIV+ cells (left) may chronically lead to downregulation of host proinflammatory gene expression in bystander cells (right) in an attempt to suppress persistent inflammation and innate immune activation. Created with [BioRender.com](https://www.biorender.com).

<https://doi.org/10.1371/journal.ppat.1011114.g008>

encoding for p53 (*TP53*) and p21 (*CDKN1A*) have previously been associated with inhibition of HIV early replication [104] and blockade of HIV infection [105]. We observed statistically significant associations for HIV total DNA and two tumor suppressor genes, *NBL1* and *P3H3*, using a stringent false discovery rate $q < 0.05$. In a recent *ex vivo* analysis of CD4+ T cells from rhesus macaques after HIV-1 Env immunization and antibody co-administration, *NBL1* was identified as a host gene that was differentially expressed in all treated (CTLA-4, PD-1, and CTLA-4 + PD-1 Ab) versus control groups [106]. Our protein validation of these two host genes associated with HIV total DNA from peripheral CD4+ T cells demonstrated similar inverse trends as observed in our RNA-seq analyses. It is unclear whether these particular genes (*P3H3* and *NBL1*) versus “tumor suppressor” genes in general, which broadly function as regulators of cell cycle, may have important roles in HIV persistence.

A much larger set of host genes were strongly associated with HIV usRNA. Since we analyzed over 20,000 genes in the human transcriptome, stringent false discovery rate (FDR)-correction methods were employed. These included data dimensionality reduction approaches (principal component analyses [36]) using whole exome data [37] and inclusion of PEER factors (probabilistic estimator of expression residuals) in multivariate models to further account for residual variability in the data [45]. Even after these additional measures, we observed 17 statistically significant genes associated with HIV usRNA that met stringent FDR $q < 0.05$ in several interrelated immune signaling pathways, many of which have been previously shown to play an important role in the host response to HIV [75–77,107–138].

We were able to perform protein validation of several of these genes reflecting secreted cytokines using matched plasma samples from 175 of the 191 study participants (encoding for IL-1 α , IL-1 β , IL-10, TNF- α , G-CSF, IP-10, TNFAIP5, and sTLR4; IL-1 α was undetectable in most of our samples despite high-sensitivity assay, potentially due to its intracellular expression [78–81]). Plasma IL-10 and TNF- α were significantly associated with HIV usRNA (TNF- α , even after adjustment for nadir CD4+ T cell count and timing of ART initiation). Interestingly, plasma IL-10 was also inversely associated with HIV total DNA. IL-10 is a complex pleiotropic cytokine that has been highly studied in several autoimmune and infectious diseases and possess complex actions that vary by stage of infection and by tissue [139]. IL-10 can both inhibit pathogen clearance and reduce excessive immunopathology, thus exhibiting both an inflammatory and regulatory response [140,141]. For example, IL-10 plays a critical role in intestinal homeostasis and both induces and prevents mucosal damage [142]. Thus, in several infectious diseases (viral, bacterial, fungal, parasitic), the effect of IL-10 varies by stage of infection and by tissue [139–141,143–148]. Here, as observed with several of the other differentially expressed host genes in relation to HIV usRNA, plasma IL-10 was inversely associated with HIV usRNA. These findings are in contrast to a recent non-human primate study by Harper et. al., where rhesus macaques ART-suppressed for 7 months demonstrated that higher plasma IL-10 levels were associated with larger SIV DNA reservoirs, suggesting that IL-10 maintains long-lived reservoir cells [75]. (The authors did not evaluate or report findings for SIV RNA but did show that *in vivo* neutralization of soluble IL-10 with a monoclonal antibody resulted in a 2-log increase in plasma IL-10). Differences in timing of ART initiation, duration of ART, and/or cross species differences might explain our contrasting findings. An alternate explanation might be that during long-term ART, IL-10 contributes to an ongoing dynamic interplay between the host immune response and low levels of HIV transcription, similar to complex host-viral dynamics that have been described associated with type I interferons during acute versus chronic infection [149].

Plasma TNF- α was the other cytokine significantly associated with HIV usRNA, consistent with the RNA-seq associations with TNF pathway genes (*TNFAIP5*, *TNFAIP6*, *TNFAIP9*). These TNF-associated pattern recognition receptors (PRRs) not only respond to TNF- α , but

also respond to IL-1 signaling and toll-like receptor (TLR) engagement [116–119], and negatively regulate NF- κ B signaling and IL-6 production [150–155]. IL-10 has been shown to block HIV-induced TNF- α and IL-6 secretion and inhibit HIV replication [156], and a cohort study of 51 people with HIV suppressed on ART demonstrated decreasing plasma IL-10/TNF- α ratio to be associated with AIDS progression [157].

The remaining host genes associated with HIV usRNA did not replicate in our limited set of protein validation assays, but collectively represent highly interrelated immune pathways that warrant further study. Plasma IL-6 significantly predicts mortality in ART-suppressed people with HIV in several large cohort studies [110–114]), and IL-1 β , an upstream inducer of IL-6, has emerged as a major target for HIV immune modulation [107,158,159]. IL-1 α can act as a “dual function” cytokine, directly sensing intracellular DNA damage as well as a proinflammatory mediator, but it is mostly found intracellularly [78,79]. We observed two toll-like receptors (TLRs) from our analyses, *TLR7* (in the differential gene expression analysis) and *TLR4* (in the pathway-based analysis), to be associated with HIV usRNA. *TLR7* encodes for a PRR that senses HIV single-stranded RNA [160,161] and has been associated with viral persistence in several human and non-human primate studies [128–130]. Host *TLR7* transcriptional activity has been linked to acute viremia in women with HIV [132] as well as with enhanced innate immune function (i.e., IFN- α and TNF- α production) [131], but *TLR7* is only expressed intracellularly [162], so we were unable to include it in our protein validation experiments. *TLR4* encodes for a PRR mediating the inflammatory response to microbial translocation [163] (e.g., bacterial endotoxin products such as lipopolysaccharide [164], which are significantly higher in people with HIV compared to uninfected individuals and are associated with AIDS progression [133–138]). *CXCL3* and *CXCL10* encode for chemokines that recruit immune cells to sites of inflammation [165,166] and signal through innate immune pathways (e.g., TLRs) [122]. IP-10 (encoded for by *CXCL10*) has been strongly linked to HIV disease progression and persistence [125–127]. *CSF3* encodes for G-CSF (granulocyte stimulating factor), which is also part of the IL-6 superfamily of cytokines [115]. G-CSF (granulocyte stimulating factor), encoded by *CSF3*, has been shown to regulate T cell responses via induction of IL-10 [167], inhibiting CD4+ and CD8+ T cell responses [168], and has been shown to increase IL-10-producing regulatory T cells (Tregs) [169].

We also identified novel associations between HIV usRNA and two genes (*KCNJ2*, *GJB2*) encoding for membrane channel proteins previously linked to HIV-1 entry and release, and cell-cell communication, respectively. Tight regulation of potassium ion concentrations have been shown to play a critical role in HIV-1 virus production in CD4+ T cells in cell culture models [170], and the HIV Nef protein has been shown to increase K+ concentrations in cells [171] while changes in K+ concentration have been shown to regulate the HIV life cycle (e.g., viral entry, replication, and release) [82]. HIV-1 has been shown to exploit gap junction protein channels to disseminate infection as well as associated inflammation even in the absence of viral replication [85, 86], and a growing body of literature strongly suggests that connexins intensify inflammation by facilitating damage-associated molecular pattern release and binding to PRRs such as TLRs [172]. From our small subset of 40 participants, however, protein expression from CD4+ T cells did not validate the RNA-seq findings.

The study has several limitations that deserve mention. First, although the HIV reservoir has been shown to be relatively stable over time [17,91,173], our cross-sectional design limits the ability to demonstrate causality and simply provides a “snapshot” of the HIV reservoir after a median of 5.1 years of ART suppression. However, based on the known functions of the significantly associated host gene, we have proposed at least two potential models that need to be further validated in longitudinal and functional genomics studies. Indeed, the true *in vivo* associations might involve more complex feedback pathways between the HIV reservoir and

host responses. Second, as is characteristic of our San Francisco-based HIV+ population, our study included mostly males of European ancestry. We accounted for this using well-established GWAS-based methods to adjust for population stratification bias [36,174], as well as the use of PEERs [45], which account for residual variance that is characteristic of RNA-seq data. Third, we quantified the peripheral CD4+ T cell reservoir, but the majority of the HIV reservoir persists in lymphoid tissues, such as in the gut-associated lymphoid tissues [175,176]. Recent data suggests that the tissue compartment largely reflects (and is the likely source of) the peripheral compartment [177–179]. While several of the genes associated with HIV usRNA reflect tissue-based inflammation (e.g., IL-10), future studies will need to determine whether our findings from the blood reservoir are relevant to the tissue HIV reservoir. We also performed bulk RNA-seq from peripheral CD4+ T cells and did not perform separate analyses by HIV-infected versus uninfected cells (given the limited availability of PBMCs for our study participants). Thus, the interpretation of our findings likely largely represents host gene expression differences among HIV-uninfected cells, given the infrequency of CD4+ T cells harboring provirus in an aliquot of 10 million cells. Finally, while we selected participants to focus on HIV “non-controllers,” our findings may also be applicable to HIV elite and/or post-treatment controllers. The purpose of this transcriptomic analysis as well as our previously published whole exome sequencing analysis [37] from this cohort were to focus on previously undescribed host genetic predictors of the HIV reservoir (signals that might be lost amidst a study population enriched for previously reported strong genetic effects, such as with HLA and/or *CCR5Δ32* [21–24]) that may be applicable to the large majority of people with HIV who are unable to suppress virus in the absence of therapy.

We did not observe statistically significant associations with HIV intact DNA and host genes. We believe that this may be because HIV intact DNA was undetectable in 48% of our measured samples (while for example, total DNA was measurable in 95% of samples). Here, we performed the HIV intact DNA assay after already allocating DNA for whole exome sequencing and for HIV total DNA quantification by qPCR [37]. Therefore, the low intact DNA detection rate may have been due to (1) low sample input DNA, (2) low true frequencies of cells containing intact proviruses, and/or (3) misclassification of “intact” provirus (primer/probe mismatches described for these type of assays [96]). We quantified HIV intact DNA by targeting five regions of the HIV genome, including regions that are highly conserved when present but are also often deleted, as well as an *Env* region with frequent hypermutations, across two droplet digital PCR reactions [31]. This allowed the analysis of potentially replication-competent (“intact”) proviral genomes by quantifying the number of droplets positive for 3 targets per each of the two reactions, and then mathematically combining the results of both reactions to calculate the number of HIV genomes containing all 5 regions (5T-IPDA). Zero intact proviral copies was assigned when either of the two reactions failed to detect all three regions in any of the droplets. While we are unable to determine potential primer-mismatches as an underlying cause (since we did not perform full-length or near full-length sequencing), this may have also influenced our results since we have previously shown that the frequency of primer mismatches is likely higher in assays interrogating a larger number of HIV-1 targets (e.g., our 5-target assay compared to a previously published 2-target assay [42]).

Overall, findings from our cross-sectional cohort identified several biologically plausible genes and immune pathways that may be associated with the HIV reservoir. In particular, we observed two host genes associated with cell cycle regulation (previously described in relation to tumor suppression) as well as several host genes involved in innate immunity and/or inflammation to be associated with peripheral measures of the HIV DNA and RNA reservoirs, respectively. Several of the inflammatory and innate immune genes and pathways associated with HIV usRNA are highly interrelated signaling pathways related to pathogen recognition

(TLRs, NLRs), inflammasome activation (IL-1, IL-6), mucosal homeostasis (IL-10, TLR4), and inflammation (TNF- α , chemokine release). In addition, we report two novel associations with genes encoding for membrane channel proteins that may play a role in these same inflammatory pathways. A limited set of protein validation assays were performed which showed that the association between IL-10 and TNF- α was also significantly inversely associated with HIV usRNA. These discovery-based transcriptomic findings add to the limited host genetic and HIV reservoir literature and suggest that while changes in host gene expression may influence the size of the HIV reservoir, host gene expression itself may in turn, vary in response to the transcriptionally active reservoir. Additional studies in larger cohorts are needed to further validate these findings.

Materials and methods

Study participants

HIV+ ART-suppressed non-controllers from the University of California San Francisco (UCSF) SCOPE and Options HIV+ cohorts were included in the study. The UCSF SCOPE and Options cohorts are prospective clinic-based cohort studies, currently with over 2500 participants to date, and are enriched for elite controllers (ECs) and post-treatment controllers (PTCs) as part of the ongoing aims (NCT00187512). Detailed interviews are conducted every 4 months, including questions regarding medications, medication adherence, and intercurrent illnesses. At each study visit, plasma HIV-1 RNA levels and CD4+ T cell counts are measured, as well as PBMC and plasma collected. Using strict clinical and laboratory criteria, Elite Controller and/or Post-Treatment Controller status is defined (e.g., for Elite Controller- Confirmed: “antiretroviral therapy-naïve subjects who have at least one year duration of documented viral loads that are below the level of detection on conventional assays up until the date of the selected specimen”). Inclusion criteria were laboratory-confirmed HIV-1 infection, availability of cryopreserved peripheral blood mononuclear cells (PBMCs), and plasma HIV RNA levels below the limit of assay quantification for at least 24 months at the time of biospecimen collection. We excluded individuals with elite or post-treatment control (as defined by clinical and laboratory data), recent hospitalization, infection requiring antibiotics, vaccination, or exposure to immunomodulatory drugs in the six months prior to sampling timepoint. The research was approved by the University of California San Francisco Committee on Human Research (CHR), and all participants provided written informed consent.

HIV reservoir quantification

Cryopreserved PBMCs were viably thawed and total CD4+ T cells were enriched via immunomagnetic selection (StemCell, Vancouver, Canada), with cell count, viability, and purity assessed by flow cytometry both before and after selection. DNA and RNA were extracted from CD4+ T cells using the AllPrep Universal Kit (Qiagen, Hilden, Germany). Quantitative PCR was performed to determine the levels of HIV-1 cell-associated RNA (HIV usRNA), proviral DNA (HIV totalDNA), and CCR5 in each subgroup. CCR5 was used to calculate assay cell concentration and extraction efficiency. Primer pairs and probe sequences were used as described in [44,180]. Briefly, the same primer and probe sequences were used for both total HIV-1 DNA and unspliced RNA and sit near the Gag-LTR junction, a highly conserved region among all group M HIV-1 sequences. PCR reactions were performed on an ABI OneStep qPCR machine (Applied Biosystems) using either the ABI TaqMan Universal PCR Master Mix for DNA or the ABI TaqMan Fast Virus 1-Step Master Mix for RNA for up to 45 cycles as we have previously described [44].

Using the remaining extracted DNA from the CD4+ T cells, we performed a multiplexed ddPCR assay targeting three regions of the HIV-1 genome to quantify the frequency of cells with “intact” HIV (a proxy for the frequency of replication-competent provirus) [31]. HIV intact DNA was quantified by targeting five regions on the HIV genome, including highly conserved regions and positions that are frequently deleted or hypermutated [31]. Optimized restriction enzyme digestion was used to prepare the genomic DNA for droplet formation while minimizing the amount of shearing within the viral genome. The protocol targeted 5 regions in the HIV genome across two triplex droplet digital PCR (ddPCR) reactions. Droplet generation and thermocycling were performed according to manufacturer instructions. Thus, the multiplex ddPCR assay allowed the analysis of potentially replication-competent (“intact”) proviral genomes by quantifying the number of droplets positive for 3 targets per reaction. Two targets in a housekeeping gene (*RPP30*) were used to quantify all cells, and a target in the T cell receptor D gene (*TRD*) was used to normalize the HIV copy numbers per 1×10^6 CD4+ T cells. A DNA shearing index (DSI) was then calculated, and mathematically corrected for residual DNA shearing as measured by *RPP30* targets to calculate the estimated number of intact proviral genomes per million CD4+ T cells after correcting for shearing [87]. As previously described, we employed a conservative approach of assigning a zero value for HIV intact DNA if one of two HIV-1 reactions were undetectable [31,87], since even one reaction with defective proviral sequence suggests non-intact HIV DNA.

Host RNA sequencing

As above for the HIV reservoir quantification, cryopreserved PBMCs were enriched for CD4+ T cells (StemCell, Vancouver, Canada), and RNA was extracted from CD4+ T cells using the AllPrep Universal Kit (Qiagen, Hilden, Germany) with one aliquot set aside for HIV reservoir quantification and a second aliquot for host RNA sequencing. RNA was quantified using Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA) and integrity checked using Tape Station (Agilent Technologies, Palo Alto, CA, USA). Standard RNA sequencing libraries were prepared using the NEBNext Ultra II RNA Library Prep Kit for Illumina using manufacturer’s instructions (New England Biolabs, Ipswich, MA, USA). Briefly, mRNAs were initially enriched with Oligod(T) beads and then fragmented for 15 minutes at 94°C. First strand and second strand cDNA were subsequently synthesized, end repaired and adenylated, and universal adapters were ligated to cDNA fragments, followed by index addition and library enrichment by PCR. For a subset of samples, ultra-Low RNA sequencing libraries were prepared with SMART-Seq v4 Ultra Low Input Kit for Sequencing for full-length cDNA synthesis and amplification (Clontech, Mountain View, CA), and Illumina Nextera XT library was used for sequencing library preparation. Briefly, cDNA was fragmented, and adaptor was added using Transposase, followed by limited-cycle PCR to enrich and add index to the cDNA fragments. Sequencing libraries were validated using the Agilent Tape Station (Agilent Technologies, Palo Alto, CA, USA), and quantified using Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). The sequencing libraries were then clustered on flowcell lanes using the Illumina NovaSeq6000 instrument according to manufacturer’s instructions and sequenced using a 2x150bp Paired End (PE) configuration. Image analysis and base calling were conducted by the NovaSeq Control Software (allowing for single mismatch for index sequence identification), and raw sequence data (.bcl files) generated from Illumina NovaSeq was converted to fastq files and de-multiplexed using Illumina’s bcl2fastq 2.19 software.

The HTStream pre-processing pipeline ([s4hts.github.io/htstream/](https://github.com/s4hts/htstream/)) was used for removing PCR duplicates, adapters, N characters, PolyA/T sequences, Phix contaminants, and poor-quality sequences (with quality score <20 with sliding window of 10 base pairs). The quality of

raw reads was assessed using FastQC [181]. All samples had a per base quality score and sequence quality score >30 . RNA-seq reads were then mapped to the human genome (GRCh38) [182] with a corresponding annotation file from the GENCODE project [183]. Alignment and gene quantification were performed using the STAR alignment tool and its quantification protocols [184–186]. Gene expression was converted to counts per million (CPM). To normalize the distribution of expression values across the experiment, the trimmed mean of M-values (TMM) [60] was used for sample-specific adjustment. Low-expressed genes (<1 CPM for all samples) were removed. The mean-variance trend was estimated [61] to assign observational weights based on predicted variance on \log_2 -counts per million (\log_2 -CPM) using the Limma-Voom pipeline [62]. After QC analyses, a total of 19,912 genes out of 60,719 were included for downstream differential gene expression analyses.

Differential gene expression analysis

Multivariate linear models were fit for each of the three HIV reservoir measures using the Limma-Voom workflow [61,62], a quantitative weighting method that utilizes variance modeling to accommodate for residual technical and/or biological heterogeneity [61]. For all analyses, in order to account for potential population stratification bias (i.e., systematic differences in results due to ancestry rather than association of genes with disease) we used well-established methods to account for this by (1) calculating and including the first five principal components (PCs) as covariates in the multivariate models [36] and (2) performing sensitivity analyses among the largest subgroup, individuals of European ancestry. Eigenvalues were calculated to generate genetic principal components (PCs) [36] to adjust for ancestry [37]. Inclusion of potential clinical covariates for sex, age, timing of ART initiation (estimated days from HIV acquisition to ART initiation), nadir CD4+ T cell count, duration of ART suppression, and maximum pre-ART viral load were tested in multivariate models. PEERs (probabilistic estimation of expression residuals) were tested for inclusion in multivariate models to control for additional systematic sources of bias [45]. Model fit was assessed using a lambda genomic coefficient close to 1 [187]. Statistical significance was determined using a false discovery rate (FDR) q-value threshold of <0.05 . Data were analyzed and visualized (ggplot2) using the R studio statistical package (2023.06.1 Build 524).

Pathway-based analyses

For each of the three HIV reservoir measures, we also performed pathway-based analyses to more broadly evaluate whether specific immune pathways were linked to each HIV reservoir measurement. Genes from the entire transcriptome were first rank-ordered by q-values from the differential gene expression analysis for each HIV reservoir measure, and then the rank-ordering was used to identify immunologic pathways that were enriched from our dataset, using the Gene Ontology Biological Processes (GO-BP) database [188]. For the HIV usRNA analyses, for which there were several statistically significant differentially expressed genes (even after multiple testing), we performed network analyses to better cluster and visualize the statistically significant results. Using ClueGo, a network analysis application [67], only statistically significant and marginally significant genes ($q < 0.25$) were included to calculate Kappa statistics that allowed more meaningful visualization of potential biologically relevant pathways (Fig 4).

Protein validation sample selection and statistical analyses

For validation of intracellularly expressed or membrane-associated encoded proteins, we performed ELISA from peripheral CD4-enriched T cells. We were able to obtain an additional

PBMC aliquot of 10 million cells for 40 of our 191 study participants. For validation of the several inflammatory pathway genes identified in association with HIV usRNA, most of the encoded proteins were secreted proteins, and thus, we performed high-sensitivity multiplex plasma cytokine quantification (Meso Scale Diagnostics) from 175 of the 191 study participants for whom we had available matched plasma. After customization, we were able to include seven proteins from our analyses (G-CSF, IP-10, TNFAIP5, IL-1 β , IL-10, TNF- α , and sTLR4). For the protein validation analyses, given the smaller sample size, we first performed Spearman correlations between the protein expression levels and corresponding gene expression levels. Next, we performed Spearman correlations between each protein level and the associated HIV reservoir measures. Several of the protein levels demonstrated a small number of individuals with outlier values; we performed sensitivity analyses with and without outliers for each protein assayed. Multivariate models for each protein were fit as described above for the RNA-seq analyses, including significant covariates for nadir CD4⁺ T cell count and timing of ART initiation for protein analyses. Linear spline models as well as nonlinear general additive models were fit; results were similar and therefore, linear model estimates are presented in the final tables given the enhanced interpretability of these results (e.g., fold-change in host protein expression per two-fold change in copies of HIV). Data were analyzed and visualized (ggplot2) using the R studio statistical package (2023.06.1 Build 524).

Preparation of cellular lysates from purified CD4⁺ T cells

CD4⁺ T cells were isolated from PBMC by negative selection, using the EasySep Human CD4⁺ T Cell Isolation Kit (StemCell Technologies, Vancouver, BC, Canada), following manufacturer's guidelines. Purified CD4⁺ cells were resuspended in 250 μ l of PBS supplemented with 2% heat-inactivated fetal bovine serum, 1 mM EDTA and a cocktail of protease inhibitors (Pierce, ThermoFisher Scientific). The Muse Human CD4 T Cell kit (Luminex, Austin, TX) in combination with the Guava Muse Cell Analyzer were used to determine the concentration and percentages of CD4⁺ T cells after the isolation. The mean purity (% CD4⁺) was 96.95% (range: 88.95%-99.33%, N = 40 samples) and the mean total number of CD4⁺ cells was 2.41x10⁶ (range: 6.07x10⁵- 5.89x10⁶, N = 40 samples). To generate cellular lysates, purified CD4⁺ T cells were subjected to three cycles of freezing/thawing, using a dry ice (frozen CO₂) /absolute ethanol mixture and a 37°C water bath. Complete lysis was verified by trypan blue staining and microscopic analysis. Lysates were spun down at 1,500 g for 10 min at 4°C (to remove cellular debris) and the supernatants diluted 1:5 with PBS and kept at -80°C until the time of protein quantification.

Quantification of intracellular protein markers in purified CD4⁺ T cells

Total protein concentration of the CD4⁺ T cell lysates was determined using the Pierce BCA assay (Thermo Fisher Scientific). The mean value obtained was 0.94 mg/ml (range: 0.66 mg/ml- 1.18 mg/ml). The list below enumerates the assays used to determine intracellular concentration of the protein markers described in the text: Human NBL1 / DAN (CLIA) ELISA Kit (LSBio, LS-F25869); Human P3H3 / LEPREL2 Sandwich ELISA Kit (LSBio, LS-F74784); KCNJ2, Human Inward rectifier potassium channel 2 ELISA Kit (MyBioSource, MBS9305840); Human Connexin 26/GJB2 ELISA Kit (Novus Biologicals, NBP2-79811) and Human TLR4 (CLIA) ELISA Kit (LSBio, LS-F29972).

Chemiluminescence or absorbance was read on a SpectraMax iD5 multi-mode plate reader (Molecular Devices, San Jose, CA) and reported in relative light units (RLU). A standard curve was constructed by plotting the log mean RLU reading for each standard on the y-axis against the log of known concentrations on the x-axis using the SoftMax Pro 7.1 software (Molecular

Devices, San Jose, CA). Data were normalized by total protein concentration to accurately reflect the total population of cells (live and dead). Briefly, a 1:5 dilution factor (based on supernatant dilution with PBS at the time of CD4+ T cell isolation) was used to calculate the concentration in the lysate before the dilution. Each protein marker was then quantified using the marker-specific ELISA (again, taking into account the 1:5 dilution performed before cryopreservation of the lysates). Data normalization was performed by dividing the concentration of each protein in the final lysate (e.g., for P3H3 in pg/ml) by the total protein concentration (mg/ml).

Quantification of plasma cytokines by MSD

Plasma levels of IP-10 (the encoded protein for *CXCL10*), G-CSF (*GCSF*) and pentraxin 3 (*TNFAIP5*) were quantified using the electrochemiluminescence-based 3-plex mesoscale discovery (MSD) platform (U-Plex mesoscale discovery, Rockville, MA); IL-10 (*IL10*), IL-1 β (*IL1B*) and TNF- α (*TNFA*) were measured in a separate 3-plex S-plex Proinflammatory panel kit, and IL-1 α (*IL1A*) was quantified by a V-plex kit. In all these assays, undiluted samples were run in duplicate following manufacturer's instructions, and protein concentrations were determined using MSD Discovery Workbench (version 4.0.13) analysis software. The light intensities from the samples were interpolated using a four-parameter logistic fit (FourPL) to a standard curve of electrochemiluminescence generated from eight calibrators of known concentrations. The lower limit of detection for each marker can be found on the manufacturer's website (MesoScale Diagnostics, <https://www.mesoscale.com/~media/files/handout/assaylist.pdf>).

Quantification of soluble TLR4 (sTLR4) in plasma by ELISA

ELISA analysis of plasma samples was performed using a human TLR4 CLIA (chemiluminescent based) kit (LSBio, Seattle, WA). TLR4 standards were made in a 1:2 dilution using the calibrator and sample diluent. The assay was performed following manufacturer's instructions. Chemiluminescence was read on a SpectraMax iD5 multi-mode plate reader (1 sec/well, read height: 1 mm, Molecular Devices, San Jose, CA) and reported in relative light units (RLU). A standard curve was constructed by plotting the log mean RLU reading for each standard on the y-axis against the log of known concentrations on the x-axis using the SoftMax Pro 7.1 software (Molecular Devices, San Jose, CA).

Supporting information

S1 Fig. Study participant sample selection flowchart. Specific inclusion and exclusion criteria are listed for each selection step and for HIV reservoir measure analysis. CPM = counts per million.
(PDF)

S2 Fig. Principal component analysis (PCA) plot of the population structure, based on our previously published host DNA exome data [37]. Principal component analysis (PCA) plot of the population structure of the full study cohort (a). Secondary PCA plot of the European ancestry subpopulation only (b) defined by the dashed box in the lower left of panel (a). Genetic PCs were calculated from genetic data from our whole exome analysis. Most of the population was of European ancestry (bottom left of (a) some continued variability. Some continued variability was observed in European ancestry subgroup (b). Self-identified race/ethnicity shown in the legend. Frequencies for participants were recorded as: White/European American (62%), Black/African American (14%), Hispanic/Latino (11%), Mixed Ethnicity/Multiracial (6%), Asian (4%), Pacific Islander (2%), Native American (<1%), and Middle

Eastern (<1%).
(PDF)

S3 Fig. Spearman correlations between three HIV reservoir measures performed from peripheral CD4+ T cells of 191 ART-suppressed people living with HIV: HIV total DNA (A, C), unspliced RNA (A-B), intact DNA (B-C).

(PDF)

S4 Fig. Spearman correlations of timing of ART initiation (years from estimated infection date to ART start date) and three HIV reservoir measures performed from peripheral CD4+ T cells of 191 ART-suppressed people living with HIV: total DNA (A), unspliced RNA (B), and intact DNA (C).

(PDF)

S5 Fig. Spearman correlations of nadir CD4+ T cell count and three HIV reservoir measures performed from peripheral CD4+ T cells of 191 ART-suppressed people living with HIV: total DNA (A), unspliced RNA (B), and intact DNA (C).

(PDF)

S6 Fig. Correlations between gene and protein expression for host genes that were associated with HIV Total DNA (*P3H3*, *NBL1*). Spearman correlations between host gene (normalized counts) are shown in relation to protein expression from peripheral CD4+ T cells among a subset of 40 participants in the study.

(PDF)

S7 Fig. Correlations between gene and protein expression for host genes that were associated with HIV usRNA (*IL10/IL-10*, *TNFA/TNF-a*, *IL1B/IL-1b*, *CSF3/G-CSF*, *CXCL10/IP-10*, *TNFAIP5/PTX3*, *TLR4/sTLR4*). Spearman correlations between host gene (normalized counts) are shown in relation to plasma protein expression among a subset of 175 participants in the study.

(PDF)

S8 Fig. Plasma cytokine expression of G-CSF, IP-10, TNFAIP5, IL-1b, IL-10, TNF-a, and sTLR4. The association between plasma protein expression among 175 study participants in relation to measures of HIV total DNA. While these immunologic pathways were identified in relation to HIV usRNA (Table 3), we were able to compare plasma cytokines in relation to HIV total DNA as an additional analysis.

(PDF)

S9 Fig. Correlations between gene and protein expression for host genes that were associated with HIV usRNA (*KCNJ2*, *GJB2*). Spearman correlations between host gene (normalized counts) are shown in relation to protein expression from peripheral CD4+ T cells among a subset of 40 participants in the study.

(PDF)

S10 Fig. HIV intact DNA quantification was correlated with sample DNA concentrations. Low levels of detection of HIV intact DNA by ddPCR can be influenced by low sample input DNA concentration, primer-mismatches of HIV-1 sequences, and/or misclassification of “intact” versus “defective” provirus [96]. HIV intact DNA was undetectable in 48% of our measured samples (while for example, total DNA by qPCR was measurable in 95% of samples,

[S3 Fig](#)).

(PDF)

S11 Fig. Proposed model for the inverse association between HIV unspliced RNA and host gene expression in our cross-sectional study of 191 ART-suppressed people living with HIV. Within bulk peripheral CD4+ T cells, higher transcriptional reservoir activity (HIV usRNA) from HIV+ cells (left) may chronically lead to downregulation of host genes encoding for membrane channel proteins involved in HIV-1 entry and release (*KCNJ2*) and cell-cell communication (*GJB2*) in bystander cells (right) in an attempt to suppress persistent cell-cell infection during chronic HIV. Created with BioRender.com.
(PDF)

S1 Table. Gene set enrichment analyses (GSEA) of ranked differentially expressed genes in relation to HIV total DNA using the Gene Ontology Biological Processes (GO-BP) database. Genes sets with Benjamini-Hochberg false discovery rate (FDR)-adjusted $q < 0.25$ are shown for the total study population (top panel) and for the European ancestry subgroup (bottom panel). Gene sets where $q < 0.05$ are shown in bold font.
(PDF)

S2 Table. Multivariate models of P3H3 and NBL1 protein expression from peripheral CD4 + T cells in relation to HIV total DNA among 40 participants.
(PDF)

S3 Table. Differentially expressed host genes associated with HIV unspliced RNA (usRNA) in the total study population (top panel) and the European ancestry subgroup (bottom panel), at a Benjamini-Hochberg false discovery rate (FDR) of $q < 0.25$, that were not shown in [Table 2](#).
(PDF)

S4 Table. Gene set enrichment analyses (GSEA) of ranked differentially expressed genes in relation to HIV unspliced RNA using the Gene Ontology Biological Processes (GO-BP) database. Genes sets with Benjamini-Hochberg false discovery rate (FDR)-adjusted $q < 0.05$ are shown for the total study population (top panel) and for the European ancestry subgroup (bottom panel). Gene sets where $q < 0.05$ are shown in bold font.
(PDF)

S5 Table. Multivariate models of plasma IL-1 β , IL-10, TNF- α , G-CSF, IP-10, TNFAIP5, and sTLR protein expression in relation to HIV unspliced RNA among 175 participants.
(PDF)

S6 Table. Multivariate models of Kir2.1 (*KCNJ2*) and Connexin 26 (*GJB2*) protein expression from peripheral CD4+ T cells in relation to HIV unspliced RNA among 40 participants.
(PDF)

S7 Table. Differentially expressed host genes in relation to HIV Intact DNA in the Total Study Population (top panel) and the European ancestry subgroup (bottom panel), at a Benjamini-Hochberg false discovery rate (FDR) of $q < 0.25$. Two-fold higher level of HIV intact DNA was associated with upregulation of genes involved in glycogen degradation (*AGL*) and inhibits thrombus (clot) degradation (*PLGLB1*).
(PDF)

S8 Table. Gene set enrichment analyses (GSEA) of ranked differentially expressed genes in relation to HIV intact DNA using the Gene Ontology Biological Processes (GO-BP) database. Genes sets with Benjamini-Hochberg false discovery rate (FDR)-adjusted $q < 0.25$ are shown for the total study population (top panel) and for the European ancestry subgroup

(bottom panel). Gene sets where $q < 0.05$ are shown in bold font.
(PDF)

Acknowledgments

The authors wish to acknowledge the participation of all the study participants who contributed to this work as well as the clinical research staff of the SCOPE and Options who made this research possible. The authors would like to acknowledge the contributions of Sannidhi Sarvadhavabhatla and Maria Sophia Donaire in facilitating sample shipment and database management for the final protein validation assays.

Author Contributions

Conceptualization: Ashok K. Dwivedi, David A. Siegel, Timothy J. Henrich, Steven G. Deeks, Sulggi A. Lee.

Data curation: Germán G. Gornalusse, David A. Siegel, Cassandra Thanh, Rebecca Hoh, Kristen S. Hobbs, Tony Pan, Erica A. Gibson, Jeffrey Milush, Meei-Li Huang, Julieta Reppetti, Phuong M. Vo, Claire N. Levy, Pavitra Roychoudhury, Keith R. Jerome, Florian Hladik, Timothy J. Henrich, Sulggi A. Lee.

Formal analysis: Ashok K. Dwivedi, Germán G. Gornalusse, David A. Siegel, Alton Barbehenn, Cassandra Thanh, Kristen S. Hobbs, Jeffrey Milush, Meei-Li Huang, Phuong M. Vo, Claire N. Levy, Pavitra Roychoudhury, Florian Hladik, Timothy J. Henrich, Sulggi A. Lee.

Funding acquisition: Germán G. Gornalusse, Michael P. Busch, Florian Hladik, Timothy J. Henrich, Steven G. Deeks, Sulggi A. Lee.

Investigation: Florian Hladik, Sulggi A. Lee.

Methodology: David A. Siegel, Timothy J. Henrich, Sulggi A. Lee.

Project administration: Rebecca Hoh, Sulggi A. Lee.

Resources: Rebecca Hoh, Jeffrey Martin, Frederick Hecht, Christopher Pilcher, Michael P. Busch, Mars Stone, Keith R. Jerome, Florian Hladik, Sulggi A. Lee.

Software: David A. Siegel, Sulggi A. Lee.

Supervision: David A. Siegel, Pavitra Roychoudhury, Keith R. Jerome, Timothy J. Henrich, Sulggi A. Lee.

Validation: Julieta Reppetti, Phuong M. Vo, Florian Hladik, Sulggi A. Lee.

Visualization: Ashok K. Dwivedi, Germán G. Gornalusse, Alton Barbehenn, Sulggi A. Lee.

Writing – original draft: Ashok K. Dwivedi, Florian Hladik, Sulggi A. Lee.

Writing – review & editing: Ashok K. Dwivedi, Germán G. Gornalusse, Florian Hladik, Sulggi A. Lee.

References

1. Turk G, Seiger K, Lian X, Sun W, Parsons EM, Gao C, et al. A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. *Ann Intern Med.* 2022; 175(1):95–100. Epub 20211116. <https://doi.org/10.7326/L21-0297> PMID: 34781719; PubMed Central PMCID: PMC9215120.
2. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med.* 2009; 360(7):692–8. Epub 2009/02/14. <https://doi.org/10.1056/NEJMoa0802905> PMID: 19213682.

3. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppas D, Salgado M, et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation. *Nature*. 2019; 568(7751):244–8. Epub 2019/03/06. <https://doi.org/10.1038/s41586-019-1027-4> PMID: 30836379; PubMed Central PMCID: PMC7275870.
4. Ndung'u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. *Nature*. 2019; 576(7787):397–405. <https://doi.org/10.1038/s41586-019-1841-8> WOS:000504660500088. PMID: 31853080
5. Katlama C, Deeks SG, Autran B, Martinez-Picado J, Van Lunzen J, Rouzioux C, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. *The Lancet*. 2013; 381(9883):2109–17. [https://doi.org/10.1016/S0140-6736\(13\)60104-X](https://doi.org/10.1016/S0140-6736(13)60104-X) PMID: 23541541
6. Esté JA, Cihlar T. Current status and challenges of antiretroviral research and therapy. *Antiviral research*. 2010; 85(1):25–33. <https://doi.org/10.1016/j.antiviral.2009.10.007> PMID: 20018390
7. Gay CL, Kuruc JD, Falcinelli SD, Warren JA, Reifeis SA, Kirchherr JL, et al. Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 infection. *Sci Rep*. 2020; 10(1):5134. Epub 2020/03/22. <https://doi.org/10.1038/s41598-020-61878-3> PMID: 32198428; PubMed Central PMCID: PMC7083965.
8. Fidler S, Stohr W, Pace M, Dorrell L, Lever A, Pett S, et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet*. 2020; 395(10227):888–98. Epub 2020/02/23. [https://doi.org/10.1016/S0140-6736\(19\)32990-3](https://doi.org/10.1016/S0140-6736(19)32990-3) PMID: 32085823.
9. Gutierrez C, Serrano-Villar S, Madrid-Elena N, Perez-Elias MJ, Martin ME, Barbas C, et al. Bryostatins for latent virus reactivation in HIV-infected patients on antiretroviral therapy. *AIDS*. 2016; 30(9):1385–92. Epub 2016/02/19. <https://doi.org/10.1097/QAD.0000000000001064> PMID: 26891037.
10. Vibholm L, Schleimann MH, Hojen JF, Benfield T, Offerens R, Rasmussen K, et al. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. *Clin Infect Dis*. 2017; 64(12):1686–95. <https://doi.org/10.1093/cid/cix201> PMID: 28329286.
11. Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, et al. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virologically Suppressed Adults Living With Human Immunodeficiency Virus-1. *Clin Infect Dis*. 2021; 72(11):e815–e24. Epub 2020/10/13. <https://doi.org/10.1093/cid/ciaa1534> PMID: 33043969.
12. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. *Lancet HIV*. 2015; 2(12):e520–9. Epub 2015/11/29. [https://doi.org/10.1016/S2352-3018\(15\)00226-X](https://doi.org/10.1016/S2352-3018(15)00226-X) PMID: 26614966; PubMed Central PMCID: PMC5108570.
13. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. *J Infect Dis*. 2007; 195(12):1762–4. Epub 2007/05/02. <https://doi.org/10.1086/518250> PMID: 17492591.
14. Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. *Journal of Antimicrobial Chemotherapy*. 2013; 68(5):1169–78. <https://doi.org/10.1093/jac/dks533> PMID: 23335199
15. Etemad B, Esmailzadeh E, Li JZ. Learning From the Exceptions: HIV Remission in Post-treatment Controllers. *Front Immunol*. 2019; 10:1749. Epub 2019/07/24. <https://doi.org/10.3389/fimmu.2019.01749> PMID: 31396237; PubMed Central PMCID: PMC6668499.
16. Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, et al. Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. *AIDS*. 2021; 35(13):2225–7. <https://doi.org/10.1097/QAD.0000000000002978> PMID: 34127579; PubMed Central PMCID: PMC8490281.
17. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. *Nat Commun*. 2019; 10(1):3193. Epub 2019/07/22. <https://doi.org/10.1038/s41467-019-10884-9> PMID: 31324762; PubMed Central PMCID: PMC6642170.
18. Gianella S, Rawlings SA, Nakazawa M, Chaillon A, Strain M, Layman L, et al. Sex differences in HIV Persistence and Reservoir Size during Aging. *Clin Infect Dis*. 2021. Epub 2021/10/06. <https://doi.org/10.1093/cid/ciab873> PMID: 34612493.
19. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does Patient Sex Affect Human Immunodeficiency Virus Levels? *Clinical Infectious Diseases*. 2002; 35(3):313–22. <https://doi.org/10.1086/341249> PMID: 12115098

20. Deeks SG, Bacchetti P, Chomont N, Karn J, Lewin SR, Solomon A, et al. Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. *The Journal of Infectious Diseases*. 2019; 219(7):1084–94. <https://doi.org/10.1093/infdis/jiy617> PMID: 30371873
21. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. *Ann Intern Med*. 1997; 127(10):882–90. Epub 1998/02/12. <https://doi.org/10.7326/0003-4819-127-10-199711150-00004> PMID: 9382366.
22. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. *Science*. 1996; 273(5283):1856–62. Epub 1996/09/27. <https://doi.org/10.1126/science.273.5283.1856> PMID: 8791590.
23. Rappaport J, Cho YY, Hendel H, Schwartz EJ, Schachter F, Zagury JF. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. *Lancet*. 1997; 349(9056):922–3. Epub 1997/03/29. [https://doi.org/10.1016/S0140-6736\(05\)62697-9](https://doi.org/10.1016/S0140-6736(05)62697-9) PMID: 9093257.
24. Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, et al. CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. *Nat Immunol*. 2019; 20(7):824–34. Epub 2019/06/19. <https://doi.org/10.1038/s41590-019-0406-1> PMID: 31209403; PubMed Central PMCID: PMC6584055.
25. Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, et al. Host Variation in Interferon, MHC Class I, Glycosylation, and Viral Transcription Genes Predict HIV Persistence. 2022. <https://doi.org/10.1101/2021.10.31.466670>
26. Francesconi M, Lehner B. The effects of genetic variation on gene expression dynamics during development. *Nature*. 2014; 505(7482):208–11. Epub 2013/11/26. <https://doi.org/10.1038/nature12772> PMID: 24270809.
27. Williams RB, Chan EK, Cowley MJ, Little PF. The influence of genetic variation on gene expression. *Genome Res*. 2007; 17(12):1707–16. Epub 2007/12/08. <https://doi.org/10.1101/gr.6981507> PMID: 18063559.
28. Yazar S, Alquicira-Hernandez J, Wing K, Senabouth A, Gordon MG, Andersen S, et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. *Science*. 2022; 376(6589):eabf3041. Epub 2022/04/08. <https://doi.org/10.1126/science.abf3041> PMID: 35389779.
29. Shahbaz S, Jovel J, Elahi S. Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors. *Clin Transl Immunology*. 2021; 10(5):e1289. Epub 2021/05/26. <https://doi.org/10.1002/cti2.1289> PMID: 34094548; PubMed Central PMCID: PMC8155695.
30. Petkov S, Chiodi F. Distinct transcriptomic profiles of naive CD4+T cells distinguish HIV-1 infected patients initiating antiretroviral therapy at acute or chronic phase of infection. *Genomics*. 2021; 113(6):3487–500. <https://doi.org/10.1016/j.ygeno.2021.08.014> WOS:000703998100004. PMID: 34425224
31. Levy CN, Hughes SM, Roychoudhury P, Reeves DB, Amstutz C, Zhu H, et al. A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. *Cell Rep Med*. 2021; 2(4):100243. Epub 2021/05/06. <https://doi.org/10.1016/j.xcrm.2021.100243> PMID: 33948574; PubMed Central PMCID: PMC8080125.
32. Ramirez CM, Sinclair E, Epling L, Lee SA, Jain V, Hsue PY, et al. Immunologic profiles distinguish aviremic HIV-infected adults. *AIDS*. 2016; 30(10):1553–62. Epub 2016/02/09. <https://doi.org/10.1097/QAD.0000000000001049> PMID: 26854811; PubMed Central PMCID: PMC5679214.
33. Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, et al. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. *PLoS One*. 2014; 9(1):e85516. Epub 2014/01/28. <https://doi.org/10.1371/journal.pone.0085516> PMID: 24465584; PubMed Central PMCID: PMC3894966.
34. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. *J Virol*. 2008; 82(11):5398–407. Epub 2008/03/21. <https://doi.org/10.1128/JVI.02176-07> PMID: 18353945; PubMed Central PMCID: PMC2395228.
35. Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. *BMC Infect Dis*. 2019; 19(1):894. Epub 2019/10/28. <https://doi.org/10.1186/s12879-019-4543-9> PMID: 31655566; PubMed Central PMCID: PMC6815418.

36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nature genetics*. 2006; 38(8):904–9. Epub 2006/07/25. <https://doi.org/10.1038/ng1847> PMID: 16862161.
37. Siegel DA, Thanh C, Wan E, Hoh R, Hobbs K, Pan T, et al. Host Variation in Type I Interferon Signaling Genes (MX1), CCR5Δ32, and MHC Class I Alleles in Treated HIV+ Non-Controllers Predict Viral Reservoir Size. *AIDS*. 2022; 10.1097(QAD.0000000000003428) PMID: <https://doi.org/10.1097/QAD.0000000000003428> PMID: 36695358
38. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent non-induced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell*. 2013; 155(3):540–51. Epub 2013/11/19. <https://doi.org/10.1016/j.cell.2013.09.020> PMID: 24243014; PubMed Central PMCID: PMC3896327.
39. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nat Med*. 2016; 22(9):1043–9. Epub 2016/08/09. <https://doi.org/10.1038/nm.4156> PMID: 27500724; PubMed Central PMCID: PMC5014606.
40. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. *EBioMedicine*. 2015; 2(8):872–81. <https://doi.org/10.1016/j.ebiom.2015.06.019> PMID: 26425694; PubMed Central PMCID: PMC4563128.
41. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS Pathog*. 2013; 9(2):e1003174. <https://doi.org/10.1371/journal.ppat.1003174> PMID: 23459007; PubMed Central PMCID: PMC3573107.
42. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature*. 2019; 566(7742):120–5. Epub 2019/02/01. <https://doi.org/10.1038/s41586-019-0898-8> PMID: 30700913.
43. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. *PLoS pathogens*. 2013; 9(2):e1003174. Epub 2013/03/06. <https://doi.org/10.1371/journal.ppat.1003174> PMID: 23459007; PubMed Central PMCID: PMC3573107.
44. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. *Nat Protoc*. 2008; 3(7):1240–8. Epub 2008/07/05. <https://doi.org/10.1038/nprot.2008.108> PMID: 18600229.
45. Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. *Nature protocols*. 2012; 7(3):500. <https://doi.org/10.1038/nprot.2011.457> PMID: 22343431
46. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. *Nucleic acids research*. 2016; 44(D1):D733–D45. <https://doi.org/10.1093/nar/gkv1189> PMID: 26553804
47. Rappu P, Salo AM, Myllyharju J, Heino J. Role of prolyl hydroxylation in the molecular interactions of collagens. *Essays in biochemistry*. 2019; 63(3):325–35. <https://doi.org/10.1042/EBC20180053> PMID: 31350381
48. Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P, et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. *British journal of cancer*. 2009; 100(10):1687–96. <https://doi.org/10.1038/sj.bjc.6605042> PMID: 19436308
49. Li Y, Chen Y, Ma Y, Nenkov M, Haase D, Petersen I. Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer. *Experimental cell research*. 2018; 363(1):121–8. <https://doi.org/10.1016/j.yexcr.2017.12.020> PMID: 29277505
50. Hatzimichael E, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, et al. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. *Eur J Haematol*. 2010; 84(1):47–51. Epub 2009/09/10. <https://doi.org/10.1111/j.1600-0609.2009.01344.x> PMID: 19737309.
51. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, et al. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. *Br J Cancer*. 2012; 107(8):1423–32. Epub 2012/09/08. <https://doi.org/10.1038/bjc.2012.380> PMID: 22955849; PubMed Central PMCID: PMC3494450.
52. Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P, et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. *Br J Cancer*. 2009; 100(10):1687–96. Epub 2009/05/14. <https://doi.org/10.1038/sj.bjc.6605042> PMID: 19436308; PubMed Central PMCID: PMC2696763.
53. Kattamuri C, Luedeke DM, Nolan K, Rankin SA, Greis KD, Zorn AM, et al. Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. *J Mol Biol*. 2012; 424(5):313–27.

- Epub 20121009. <https://doi.org/10.1016/j.jmb.2012.10.003> PMID: 23063586; PubMed Central PMCID: PMC3509953.
54. Hung WT, Wu FJ, Wang CJ, Luo CW. DAN (NBL1) specifically antagonizes BMP2 and BMP4 and modulates the actions of GDF9, BMP2, and BMP4 in the rat ovary. *Biol Reprod.* 2012; 86(5):158, 1–9. Epub 20120531. <https://doi.org/10.1095/biolreprod.111.096172> PMID: 22357543.
 55. Ozaki T, Nakamura Y, Enomoto H, Hirose M, Sakiyama S. Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of the entry into the S phase. *Cancer Res.* 1995; 55(4):895–900. PMID: 7850806.
 56. Sung JC, McCarthy S, Turner J, Li CG, Yeatman TJ. The NBL1 tumor suppressor gene is downregulated in colon cancer by promoter methylation. *Journal of the American College of Surgeons.* 2004; 199(3). <https://doi.org/10.1016/j.jamcollsurg.2004.05.200>
 57. Hayashi T, Sentani K, Oue N, Ohara S, Teishima J, Anami K, et al. The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression. *Pathobiology.* 2013; 80(2):60–9. Epub 20120829. <https://doi.org/10.1159/000341396> PMID: 22948749.
 58. Nakamura Y, Ozaki T, Ichimiya S, Nakagawara A, Sakiyama S. Ectopic expression of DAN enhances the retinoic acid-induced neuronal differentiation in human neuroblastoma cell lines. *Biochem Biophys Res Commun.* 1998; 243(3):722–6. <https://doi.org/10.1006/bbrc.1998.8112> PMID: 9500977.
 59. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The Human Cell Atlas. *eLife.* 2017; 6. <https://doi.org/10.7554/eLife.27041> PMID: 29206104; PubMed Central PMCID: PMC5762154.
 60. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome biology.* 2010; 11(3):1–9. <https://doi.org/10.1186/gb-2010-11-3-r25> PMID: 20196867
 61. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome biology.* 2014; 15(2):1–17. <https://doi.org/10.1186/gb-2014-15-2-r29> PMID: 24485249
 62. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic acids research.* 2015; 43(7):e47–e. <https://doi.org/10.1093/nar/gkv007> PMID: 25605792
 63. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. *Science.* 2015; 347(6220):1260419. <https://doi.org/10.1126/science.1260419> PMID: 25613900.
 64. Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. *Science.* 2020; 367(6482). <https://doi.org/10.1126/science.aay5947> PMID: 32139519.
 65. Astorga-Gamaza A, Buzon MJ. The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence. *Curr Opin HIV AIDS.* 2021; 16(4):193–9. <https://doi.org/10.1097/COH.0000000000000685> PMID: 33973900.
 66. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. *Annu Rev Immunol.* 2000; 18:665–708. <https://doi.org/10.1146/annurev.immunol.18.1.665> PMID: 10837072.
 67. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics.* 2009; 25(8):1091–3. Epub 20090223. <https://doi.org/10.1093/bioinformatics/btp101> PMID: 19237447; PubMed Central PMCID: PMC2666812.
 68. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. *Immunity.* 2019; 50(4):778–95. Epub 2019/04/18. <https://doi.org/10.1016/j.immuni.2019.03.012> PMID: 30995499; PubMed Central PMCID: PMC7174020.
 69. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. *Nat Rev Rheumatol.* 2010; 6(4):232–41. Epub 2010/02/24. <https://doi.org/10.1038/nrrheum.2010.4> PMID: 20177398.
 70. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. *Annu Rev Immunol.* 2009; 27:519–50. Epub 2009/03/24. <https://doi.org/10.1146/annurev.immunol.021908.132612> PMID: 19302047.
 71. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. *Cell Discov.* 2020; 6:36. Epub 2020/06/19. <https://doi.org/10.1038/s41421-020-0167-x> PMID: 32550001; PubMed Central PMCID: PMC7280307.

72. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med*. 2006; 12(12):1365–71. Epub 2006/11/23. <https://doi.org/10.1038/nm1511> [pii] PMID: 17115046.
73. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. *Sci Transl Med*. 2013;5(193):193ra91. Epub 2013/07/12. <https://doi.org/10.1126/scitranslmed.3006438> PMID: 23843452; PubMed Central PMCID: PMC4094294.
74. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. *AIDS*. 2015; 29(1):43–51. <https://doi.org/10.1097/QAD.0000000000000511> PMID: 25387317; PubMed Central PMCID: PMC4444362.
75. Harper J, Ribeiro SP, Chan CN, Aid M, Deleage C, Micci L, et al. Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy. *J Clin Invest*. 2022; 132(8). Epub 2022/03/02. <https://doi.org/10.1172/JCI155251> PMID: 35230978; PubMed Central PMCID: PMC9012284.
76. Ribeiro SP, Aid M, Dupuy FP, Chan CN, Hultquist JF, Delage C, et al. IL-10 driven memory T cell survival and Tfh differentiation promote HIV 2 persistence. *BioRxiv*. 2022. <https://doi.org/10.1101/2021.02.26.432955>
77. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. *Nature medicine*. 2010; 16(4):452–9. Epub 2010/03/09. <https://doi.org/10.1038/nm.2106> PMID: 20208540.
78. Spiekstra SW, Toebak MJ, Sampat-Sardjoeopersad S, van Beek PJ, Boorsma DM, Stoof TJ, et al. Induction of cytokine (interleukin-1alpha and tumor necrosis factor-alpha) and chemokine (CCL20, CCL27, and CXCL8) alarm signals after allergen and irritant exposure. *Exp Dermatol*. 2005; 14(2):109–16. <https://doi.org/10.1111/j.0906-6705.2005.00226.x> PMID: 15679580.
79. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelm Y, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. *Proc Natl Acad Sci U S A*. 2004; 101(8):2434–9. <https://doi.org/10.1073/pnas.0308705101> PMID: 14983027; PubMed Central PMCID: PMC356968.
80. Maekawa T, Jinnin M, Ohtsuki M, Ihn H. Serum levels of interleukin-1alpha in patients with systemic sclerosis. *J Dermatol*. 2013; 40(2):98–101. Epub 2012/10/18. <https://doi.org/10.1111/1346-8138.12011> PMID: 23078215.
81. Eastgate JA, Symons JA, Wood NC, Capper SJ, Duff GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis. *Br J Rheumatol*. 1991; 30(4):295–7. <https://doi.org/10.1093/rheumatology/30.4.295> PMID: 1863828.
82. Dubey RC, Mishra N, Gaur R. G protein-coupled and ATP-sensitive inwardly rectifying potassium ion channels are essential for HIV entry. *Scientific reports*. 2019; 9(1):1–9.
83. Sáez JC, Nicholson B. Connexin and Pannexin Based Channels in the Nervous System. *From Molecules to Networks 2014*. p. 257–83.
84. Goodenough DA, Paul DL. Gap Junctions. *Cold Spring Harbor Perspectives in Biology*. 2009; 1(1):a002576–a. <https://doi.org/10.1101/cshperspect.a002576> PMID: 20066080
85. Malik S, Eugenin EA. Role of Connexin and Pannexin containing channels in HIV infection and NeuroAIDS. *Neuroscience Letters*. 2019; 695:86–90. <https://doi.org/10.1016/j.neulet.2017.09.005> PMID: 28886986
86. Valdebenito S, Barreto A, Eugenin EA. The role of connexin and pannexin containing channels in the innate and acquired immune response. *Biochimica et Biophysica Acta (BBA)—Biomembranes*. 2018; 1860(1):154–65. <https://doi.org/10.1016/j.bbamem.2017.05.015> PMID: 28559189
87. Levy CN, Hughes SM, Roychoudhury P, Amstuz C, Zhu H, Huang ML, et al. HIV reservoir quantification by five-target multiplex droplet digital PCR. *STAR Protoc*. 2021; 2(4):100885. Epub 2021/10/11. <https://doi.org/10.1016/j.xpro.2021.100885> PMID: 34693363; PubMed Central PMCID: PMC8517383.
88. Simonetti FR, White JA, Tumiottio C, Ritter KD, Cai M, Gandhi RT, et al. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. *Proc Natl Acad Sci U S A*. 2020; 117(31):18692–700. Epub 2020/07/20. <https://doi.org/10.1073/pnas.2006816117> PMID: 32690683; PubMed Central PMCID: PMC7414172.
89. Falcinelli SD, Shook-Sa BE, Dewey MG, Sridhar S, Read J, Kirchherr J, et al. Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. *J Infect Dis*. 2020; 222(11):1843–52. Epub 2020/06/05. <https://doi.org/10.1093/infdis/jiaa298> PMID: 32496542; PubMed Central PMCID: PMC7653086.
90. Bruner KM. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. *Nature*. 2019;566. <https://doi.org/10.1038/s41586-019-0898-8> PMID: 30700913

91. Peluso MJ, Bacchetti P, Ritter KD, Beg S, Lai J, Martin JN, et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. *JCI Insight*. 2020; 5(4). Epub 2020/02/12. <https://doi.org/10.1172/jci.insight.132997> PMID: 32045386; PubMed Central PMCID: PMC7101154.
92. Gandhi RT, Cyktor JC, Bosch RJ, Mar H, Laird GM, Martin A, et al. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. *J Infect Dis*. 2021; 223(2):225–33. Epub 2020/08/22. <https://doi.org/10.1093/infdis/jiaa532> PMID: 32823274; PubMed Central PMCID: PMC7857155.
93. Papasavvas E, Azzoni L, Ross BN, Fair M, Yuan Z, Gyampoh K, et al. Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressing Antiretroviral Therapy. *Clin Infect Dis*. 2021; 72(3):495–8. <https://doi.org/10.1093/cid/ciaa809> PMID: 33527127; PubMed Central PMCID: PMC7850524.
94. Garliss CC, Kwaa AK, Blankson JN. A Comparison of Different Immune Activation Strategies to Reverse HIV-1 Latency. *Open Forum Infect Dis*. 2020; 7(4):ofaa082. Epub 20200304. <https://doi.org/10.1093/ofid/ofaa082> PMID: 32284948; PubMed Central PMCID: PMC7139987.
95. Kwaa AK, Garliss CC, Ritter KD, Laird GM, Blankson JN. Elite suppressors have low frequencies of intact HIV-1 proviral DNA. *AIDS*. 2020; 34(4):641–3. <https://doi.org/10.1097/QAD.0000000000002474> PMID: 31895150; PubMed Central PMCID: PMC7610219.
96. Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, et al. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). *Nat Commun*. 2021; 12(1):165. Epub 2021/01/10. <https://doi.org/10.1038/s41467-020-20442-3> PMID: 33420062; PubMed Central PMCID: PMC7794580.
97. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. *Science*. 2014; 345(6193):179–83. Epub 2014/06/28. <https://doi.org/10.1126/science.1254194> PMID: 24968937.
98. Ikeda T, Shibata J, Yoshimura K, Koito A, Matsushita S. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. *J Infect Dis*. 2007; 195(5):716–25. <https://doi.org/10.1086/510915> PMID: 17262715.
99. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. *Science*. 2014; 345(6196):570–3. Epub 2014/07/12. <https://doi.org/10.1126/science.1256304> PMID: 25011556; PubMed Central PMCID: PMC4230336.
100. Imamichi H, Natarajan V, Adelsberger JW, Rehm CA, Lempicki RA, Das B, et al. Lifespan of effector memory CD4+ T cells determined by replication-incompetent integrated HIV-1 provirus. *AIDS*. 2014; 28(8):1091–9. <https://doi.org/10.1097/QAD.0000000000000223> PMID: 24492253.
101. Kok YL, Vongrad V, Chaudron SE, Shilaih M, Leemann C, Neumann K, et al. HIV-1 integration sites in CD4+ T cells during primary, chronic, and late presentation of HIV-1 infection. *JCI Insight*. 2021; 6(9). Epub 20210510. <https://doi.org/10.1172/jci.insight.143940> PMID: 33784259; PubMed Central PMCID: PMC8262285.
102. Symons J, Chopra A, Leary S, Cooper D, Anderson JL, Chang JJ, et al., editors. HIV integration sites in CD4+ T cells from virally suppressed individuals show clonal expansion but no preferential location in oncogenes. #MOAA0104. International AIDS Society Conference; 2017; Paris, France.
103. Roychoudhury P, Haworth KG, Zhu H, Levy C, Huang M, Thanh C, et al., editors. High-throughput characterization of HIV latent reservoir demonstrates integration into genes associated with inflammation, cell cycle, and nuclear envelope assembly, enrichment in accessible chromatin, and large amounts of defective provirus. 23rd International AIDS Conference; 2020 July; San Francisco, CA, U. S.A. (Virtual).
104. Shi B, Sharifi HJ, DiGrigoli S, Kinnetz M, Mellon K, Hu W, et al. Inhibition of HIV early replication by the p53 and its downstream gene p21. *Virology Journal*. 2018; 15(1). <https://doi.org/10.1186/s12985-018-0959-x> PMID: 29587790
105. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. *Journal of Clinical Investigation*. 2011; 121(4):1549–60. <https://doi.org/10.1172/JCI44539> PMID: 21403397
106. Bradley T, Kuraoka M, Yeh CH, Tian M, Chen H, Cain DW, et al. Immune checkpoint modulation enhances HIV-1 antibody induction. *Nat Commun*. 2020; 11(1):948. Epub 2020/02/23. <https://doi.org/10.1038/s41467-020-14670-w> PMID: 32075963; PubMed Central PMCID: PMC7031230.
107. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. *Circ Res*. 2016; 118(1):145–56. <https://doi.org/10.1161/CIRCRESAHA.115.306656> PMID: 26837745; PubMed Central PMCID: PMC4793711.

108. Kuller LH, Tracy R, Bellosso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. *PLoS Med*. 2008; 5(10):e203. <https://doi.org/10.1371/journal.pmed.0050203> PMID: 18942885.
109. Sunil M, Nigalye M, Somasunderam A, Martinez ML, Yu X, Arduino RC, et al. Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People. *AIDS Res Hum Retroviruses*. 2016; 32(12):1205–9. <https://doi.org/10.1089/AID.2016.0007> PMID: 27344921; PubMed Central PMCID: PMC5175436.
110. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. *The Journal of Infectious Diseases*. 2014; 210(8):1248–59. Epub 2014/05/06. <https://doi.org/10.1093/infdis/jiu254> PMID: 24795473; PubMed Central PMCID: PMC4192039.
111. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. *PLoS One*. 2016; 11(5):e0155100. <https://doi.org/10.1371/journal.pone.0155100> PMID: 27171281; PubMed Central PMCID: PMC4865234.
112. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. *The Journal of Infectious Diseases*. 2014; 210(8):1228–38. Epub 2014/04/24. <https://doi.org/10.1093/infdis/jiu238> PMID: 24755434; PubMed Central PMCID: PMC4192038.
113. Lee SL, Byakwaga H, Boum Y, Burdo T, Williams KC, Lederman MM, et al. Immunologic Pathways that Predict Mortality in HIV-Infected Ugandans Initiating ART. *The Journal of Infectious Diseases*. 2017; In Review.
114. So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, et al. Do Biomarkers of Inflammation, Monocyte Activation, and Altered Coagulation Explain Excess Mortality Between HIV Infected and Uninfected People? *J Acquir Immune Defic Syndr*. 2016; 72(2):206–13. <https://doi.org/10.1097/QAI.0000000000000954> PMID: 27824677.
115. Unver N, McAllister F. IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets. *Cytokine & Growth Factor Reviews*. 2018; 41:10–7. <https://doi.org/10.1016/j.cytogfr.2018.04.004> PMID: 29699936
116. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. *J Biol Chem*. 1992; 267(31):22190–7. PMID: 1429570.
117. Porte R, Davoudian S, Asgari F, Parente R, Mantovani A, Garlanda C, et al. The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis. *Frontiers in Immunology*. 2019;10. <https://doi.org/10.3389/fimmu.2019.00794> PMID: 31031772
118. Lee TH, Klampfer L, Shows TB, Vilcek J. Transcriptional regulation of TSG6, a tumor necrosis factor- and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. *J Biol Chem*. 1993; 268(9):6154–60. PMID: 8454591.
119. Mittal M, Tirupathi C, Nepal S, Zhao YY, Grzych D, Soni D, et al. TNFalpha-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. *Proc Natl Acad Sci U S A*. 2016; 113(50):E8151–E8. Epub 2016/11/28. <https://doi.org/10.1073/pnas.1614935113> PMID: 27911817; PubMed Central PMCID: PMC5167170.
120. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. *Endocr Rev*. 2007; 28(5):492–520. Epub 2007/05/02. <https://doi.org/10.1210/er.2006-0044> PMID: 17475924.
121. Smit MJ, Verdijk P, van der Raaij-Helmer EM, Navis M, Hensbergen PJ, Leurs R, et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. *Blood*. 2003; 102(6):1959–65. Epub 2003/05/15. <https://doi.org/10.1182/blood-2002-12-3945> PMID: 12750173.
122. Simmons RP, Scully EP, Groden EE, Arnold KB, Chang JJ, Lane K, et al. HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways. *AIDS*. 2013; 27(16):2505–17. Epub 2013/10/08. <https://doi.org/10.1097/01.aids.0000432455.06476.bc> PMID: 24096630; PubMed Central PMCID: PMC4288813.
123. Gray CM, Liovat A-S, Rey-Cuillé M-A, Lécroux C, Jacquelin B, Girault I, et al. Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection. *PLoS ONE*. 2012; 7(10). <https://doi.org/10.1371/journal.pone.0046143> PMID: 23056251
124. Valverde-Villegas JM, de Medeiros RM, Ellwanger JH, Santos BR, Melo MG, Almeida SEM, et al. High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection. *Infect Genet*

- Evol. 2018; 57:51–8. Epub 2017/11/11. <https://doi.org/10.1016/j.meegid.2017.11.002> PMID: 29122683.
125. Pastor L, Casellas A, Carrillo J, Alonso S, Parker E, Fuente-Soro L, et al. IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings. *Sci Rep*. 2017; 7(1):8104. Epub 2017/08/16. <https://doi.org/10.1038/s41598-017-08218-0> PMID: 28808319; PubMed Central PMCID: PMC5556096.
 126. Wang Z, Yin X, Ma M, Ge H, Lang B, Sun H, et al. IP-10 Promotes Latent HIV Infection in Resting Memory CD4(+) T Cells via LIMK-Cofilin Pathway. *Front Immunol*. 2021; 12:656663. Epub 2021/08/28. <https://doi.org/10.3389/fimmu.2021.656663> PMID: 34447368; PubMed Central PMCID: PMC8383741.
 127. Cameron PU, Saleh S, Sallmann G, Solomon A, Wightman F, Evans VA, et al. Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton. *Proc Natl Acad Sci U S A*. 2010; 107(39):16934–9. Epub 2010/09/15. <https://doi.org/10.1073/pnas.1002894107> PMID: 20837531; PubMed Central PMCID: PMC2947912.
 128. Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu W-H, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. *Nature*. 2018; 563(7731):360–4. <https://doi.org/10.1038/s41586-018-0600-6> PMID: 30283138
 129. Lim S-Y, Osuna CE, Hraber PT, Hesselgesser J, Gerold JM, Barnes TL, et al. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. *Science Translational Medicine*. 2018; 10(439). <https://doi.org/10.1126/scitranslmed.aao4521> PMID: 29720451
 130. SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. *Sci Transl Med*. 2021; 13(599). Epub 2021/06/25. <https://doi.org/10.1126/scitranslmed.abg3071> PMID: 34162752.
 131. Abbas F, Cenac C, Youness A, Azar P, Delobel P, Guery JC. HIV-1 infection enhances innate function and TLR7 expression in female plasmacytoid dendritic cells. *Life Sci Alliance*. 2022; 5(10). Epub 2022/10/23. <https://doi.org/10.26508/lsa.202201452> PMID: 36271499; PubMed Central PMCID: PMC9441429.
 132. Azar P, Mejia JE, Cenac C, Shaiykova A, Youness A, Laffont S, et al. TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. *JCI Insight*. 2020; 5(12). Epub 2020/06/20. <https://doi.org/10.1172/jci.insight.136047> PMID: 32554924; PubMed Central PMCID: PMC7406249.
 133. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. *Trends Microbiol*. 2013; 21(1):6–13. Epub 2012/10/11. <https://doi.org/10.1016/j.tim.2012.09.001> PMID: 23062765; PubMed Central PMCID: PMC3534808.
 134. Younas M, Psomas C, Reynes C, Cezar R, Kundura L, Portales P, et al. Microbial Translocation Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults With Suppressed Viremia. *Front Immunol*. 2019; 10:2185. Epub 2019/09/13. <https://doi.org/10.3389/fimmu.2019.02185> PMID: 31572392; PubMed Central PMCID: PMC6753629.
 135. Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, et al. Translocated microbiome composition determines immunological outcome in treated HIV infection. *Cell*. 2021; 184(15):3899–914 e16. Epub 2021/07/09. <https://doi.org/10.1016/j.cell.2021.05.023> PMID: 34237254; PubMed Central PMCID: PMC8316372.
 136. Massanella M, Fromentin R, Chomont N. Residual inflammation and viral reservoirs: alliance against an HIV cure. *Curr Opin HIV AIDS*. 2016; 11(2):234–41. Epub 2015/11/18. <https://doi.org/10.1097/COH.0000000000000230> PMID: 26575148; PubMed Central PMCID: PMC4743501.
 137. Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E. The gut microbiome in human immunodeficiency virus infection. *BMC Med*. 2016; 14(1):83. Epub 2016/06/04. <https://doi.org/10.1186/s12916-016-0625-3> PMID: 27256449; PubMed Central PMCID: PMC4891875.
 138. Zevin AS, McKinnon L, Burgener A, Klatt NR. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. *Curr Opin HIV AIDS*. 2016; 11(2):182–90. Epub 2015/12/19. <https://doi.org/10.1097/COH.0000000000000234> PMID: 26679414; PubMed Central PMCID: PMC4752849.
 139. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. *J Immunol*. 2008; 180(9):5771–7. <https://doi.org/10.4049/jimmunol.180.9.5771> PMID: 18424693.
 140. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. *AIDS Res Hum Retroviruses*. 2006; 22(8):757–62. <https://doi.org/10.1089/aid.2006.22.757> PMID: 16910831; PubMed Central PMCID: PMC2431151.

141. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. Proinflammatory effects of IL-10 during human endotoxemia. *J Immunol.* 2000; 165(5):2783–9. Epub 2000/08/18. <https://doi.org/10.4049/jimmunol.165.5.2783> PMID: 10946310.
142. Wei HX, Wang B, Li B. IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology. *Front Immunol.* 2020; 11:1315. Epub 20200626. <https://doi.org/10.3389/fimmu.2020.01315> PMID: 32670290; PubMed Central PMCID: PMC7332769.
143. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell.* 1993; 75(2):263–74. Epub 1993/10/22. [https://doi.org/10.1016/0092-8674\(93\)80068-p](https://doi.org/10.1016/0092-8674(93)80068-p) PMID: 8402911.
144. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun.* 1998; 66(11):5224–31. Epub 1998/10/24. <https://doi.org/10.1128/IAI.66.11.5224-5231.1998> PMID: 9784526; PubMed Central PMCID: PMC108652.
145. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. *Clin Exp Rheumatol.* 1998; 16(3):283–8. Epub 1998/06/19. PMID: 9631750.
146. Lu L, Zhang H, Dauphars DJ, He YW. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis. *Trends Immunol.* 2021; 42(1):3–5. Epub 2020/11/21. <https://doi.org/10.1016/j.it.2020.10.012> PMID: 33214057; PubMed Central PMCID: PMC7605819.
147. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020; 9(1):1123–30. Epub 2020/06/02. <https://doi.org/10.1080/22221751.2020.1770129> PMID: 32475230; PubMed Central PMCID: PMC7473317.
148. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. *JCI Insight.* 2020; 5(13). Epub 2020/06/06. <https://doi.org/10.1172/jci.insight.139834> PMID: 32501293; PubMed Central PMCID: PMC7406242.
149. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature.* 2014; 511(7511):601–5. Epub 20140709. <https://doi.org/10.1038/nature13554> PMID: 25043006; PubMed Central PMCID: PMC4418221.
150. Takai C, Matsumoto I, Inoue A, Umeda N, Tanaka Y, Kurashima Y, et al. Specific overexpression of tumour necrosis factor- α -induced protein (TNFAIP)9 in CD14+CD16– monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3. *Clinical and Experimental Immunology.* 2015; 180(3):458–66. <https://doi.org/10.1111/cei.12606> PMID: 25683200
151. Inoue A, Matsumoto I, Tanaka Y, Umeda N, Tanaka Y, Mihara M, et al. Murine tumor necrosis factor α -induced adipose-related protein (tumor necrosis factor α -induced protein 9) deficiency leads to arthritis via interleukin-6 overproduction with enhanced NF- κ B, STAT-3 signaling, and dysregulated apoptosis of macrophages. *Arthritis & Rheumatism.* 2012; 64(12):3877–85. <https://doi.org/10.1002/art.34666> PMID: 22886597
152. Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. *Nat Metab.* 2021; 3(10):1302–12. Epub 20211014. <https://doi.org/10.1038/s42255-021-00470-z> PMID: 34650277.
153. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. *Nature.* 1986; 320(6063):584–8. <https://doi.org/10.1038/320584a0> PMID: 3010124.
154. Bradley JR. TNF-mediated inflammatory disease. *J Pathol.* 2008; 214(2):149–60. <https://doi.org/10.1002/path.2287> PMID: 18161752.
155. Pasquereau S, Kumar A, Herbein G. Targeting TNF and TNF Receptor Pathway in HIV-1 Infection: from Immune Activation to Viral Reservoirs. *Viruses.* 2017; 9(4). Epub 20170330. <https://doi.org/10.3390/v9040064> PMID: 28358311; PubMed Central PMCID: PMC5408670.
156. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin 6 induction of virus. *AIDS Res Hum Retroviruses.* 1994; 10(10):1199–206. <https://doi.org/10.1089/aid.1994.10.1199> PMID: 7848677.
157. Stylianou E, Aukrust P, Kvale D, Muller F, Froland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression—down-regulatory effect of potent anti-retroviral therapy. *Clin Exp Immunol.* 1999; 116(1):115–20. <https://doi.org/10.1046/j.1365-2249.1999.00865.x> PMID: 10209514; PubMed Central PMCID: PMC1905221.
158. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood.* 2011; 117(14):3720–32. <https://doi.org/10.1182/blood-2010-07-273417> PMID: 21304099; PubMed Central PMCID: PMC3083294.

159. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017; 390(10105):1833–42. [https://doi.org/10.1016/S0140-6736\(17\)32247-X](https://doi.org/10.1016/S0140-6736(17)32247-X) PMID: 28855077.
160. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science*. 2004; 303(5663):1529–31. <https://doi.org/10.1126/science.1093616> PMID: 14976261.
161. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science*. 2004; 303(5663):1526–9. Epub 2004/02/21. <https://doi.org/10.1126/science.1093620> PMID: 14976262.
162. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol*. 2010; 11(5):373–84. Epub 20100420. <https://doi.org/10.1038/ni.1863> PMID: 20404851.
163. Molteni M, Gemma S, Rossetti C. The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation. *Mediators Inflamm*. 2016; 2016:6978936. Epub 20160518. <https://doi.org/10.1155/2016/6978936> PMID: 27293318; PubMed Central PMCID: PMC4887650.
164. Guedia J, Brun P, Bhave S, Fitting S, Kang M, Dewey WL, et al. HIV-1 Tat exacerbates lipopolysaccharide-induced cytokine release via TLR4 signaling in the enteric nervous system. *Sci Rep*. 2016; 6:31203. Epub 20160805. <https://doi.org/10.1038/srep31203> PMID: 27491828; PubMed Central PMCID: PMC4974559.
165. Groves D, Jiang Y. Chemokines, a family of chemotactic cytokines. *Critical Reviews in Oral Biology & Medicine*. 1995; 6(2):109–18.
166. Foley JF, Yu C-R, Solow R, Yacobucci M, Peden KWC, Farber JM. Roles for CXC Chemokine Ligands 10 and 11 in Recruiting CD4+T Cells to HIV-1-Infected Monocyte-Derived Macrophages, Dendritic Cells, and Lymph Nodes. *The Journal of Immunology*. 2005; 174(8):4892–900. <https://doi.org/10.4049/jimmunol.174.8.4892> PMID: 15814716
167. Hollmen M, Karaman S, Schwager S, Lisibach A, Christiansen AJ, Maksimow M, et al. G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. *Oncimmunology*. 2016; 5(3):e1115177. Epub 20151124. <https://doi.org/10.1080/2162402X.2015.1115177> PMID: 27141367; PubMed Central PMCID: PMC4839343.
168. Karagiannidis I, Jerman SJ, Jacenik D, Phinney BB, Yao R, Prossnitz ER, et al. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets. *Front Immunol*. 2020; 11:1885. Epub 20200915. <https://doi.org/10.3389/fimmu.2020.01885> PMID: 33042110; PubMed Central PMCID: PMC7522314.
169. Morris ES, MacDonald KP, Rowe V, Johnson DH, Banovic T, Clouston AD, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. *Blood*. 2004; 103(9):3573–81. Epub 20040115. <https://doi.org/10.1182/blood-2003-08-2864> PMID: 14726406.
170. Choi B, Gatti PJ, Haislip AM, Fermin CD, Garry RF. Role of potassium in human immunodeficiency virus production and cytopathic effects. *Virology*. 1998; 247(2):189–99. <https://doi.org/10.1006/viro.1998.9251> PMID: 9705912
171. Choi B, Fermin CD, Comardelle AM, Haislip AM, Voss TG, Garry RF. Alterations in intracellular potassium concentration by HIV-1 and SIV Nef. *Virology*. 2008; 378(1):1–10. Epub 20080519. <https://doi.org/10.1016/j.virol.2008.05.019> PMID: 18489774; PubMed Central PMCID: PMC2396157.
172. Peng B, Xu C, Wang S, Zhang Y, Li W. The Role of Connexin Hemichannels in Inflammatory Diseases. *Biology (Basel)*. 2022; 11(2). Epub 20220202. <https://doi.org/10.3390/biology11020237> PMID: 35205103; PubMed Central PMCID: PMC8869213.
173. Falcinelli SD, Kilpatrick KW, Read J, Murtagh R, Allard B, Ghofrani S, et al. Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. *J Infect Dis*. 2021; 224(1):92–100. Epub 2020/11/21. <https://doi.org/10.1093/infdis/jiaa718> PMID: 33216132; PubMed Central PMCID: PMC8253129.
174. Gogarten SM, Sofer T, Chen H, Yu C, Brody JA, Thornton TA, et al. Genetic association testing using the GENESIS R/Bioconductor package. *Bioinformatics*. 2019; 35(24):5346–8. Epub 2019/07/23. <https://doi.org/10.1093/bioinformatics/btz567> PMID: 31329242; PubMed Central PMCID: PMC7904076.
175. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. *Proc Natl Acad Sci U S A*. 1991; 88(21):9838–42. Epub 1991/11/01. <https://doi.org/10.1073/pnas.88.21.9838> PMID: 1682922; PubMed Central PMCID: PMC52816.

176. Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, et al. Defining total-body AIDS-virus burden with implications for curative strategies. *Nat Med*. 2017; 23(11):1271–6. <https://doi.org/10.1038/nm.4411> PMID: 28967921.
177. Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. *PLoS Pathog*. 2012; 8(2):e1002506. Epub 2012/02/10. <https://doi.org/10.1371/journal.ppat.1002506> PMID: 22319447; PubMed Central PMCID: PMC3271083.
178. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, et al. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. *Proc Natl Acad Sci U S A*. 2013; 110(51):E4987–96. <https://doi.org/10.1073/pnas.1308313110> PMID: 24277811; PubMed Central PMCID: PMC3870728.
179. Imamichi H, Degray G, Dewar RL, Mannon P, Yao M, Chairez C, et al. Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. *J Infect Dis*. 2011; 204(2):309–14. Epub 2011/06/16. <https://doi.org/10.1093/infdis/jir259> PMID: 21673043; PubMed Central PMCID: PMC3114472.
180. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. *J Virol Methods*. 2012; 186(1–2):68–72. Epub 2012/09/04. <https://doi.org/10.1016/j.jviromet.2012.08.019> PMID: 22974526; PubMed Central PMCID: PMC3517891.
181. Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. 2017.
182. Schneider VA, Graves-Lindsay T, Howe K, Bouk N, Chen H-C, Kitts PA, et al. Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly. *Genome Research*. 2017; 27(5):849–64. <https://doi.org/10.1101/gr.213611.116> PMID: 28396521
183. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome research*. 2012; 22(9):1760–74. <https://doi.org/10.1101/gr.135350.111> PMID: 22955987
184. Dobin A, Gingeras TR. Mapping RNA-seq reads with STAR. *Current protocols in bioinformatics*. 2015; 51(1):11.4. 1–4. 9. <https://doi.org/10.1002/0471250953.bi1114s51> PMID: 26334920
185. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC bioinformatics*. 2011; 12(1):1–16.
186. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29(1):15–21. <https://doi.org/10.1093/bioinformatics/bts635> PMID: 23104886
187. Devlin B, Roeder K. Genomic control for association studies. *Biometrics*. 1999; 55(4):997–1004. <https://doi.org/10.1111/j.0006-341x.1999.00997.x> PMID: 11315092
188. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omic: a journal of integrative biology*. 2012; 16(5):284–7. <https://doi.org/10.1089/omi.2011.0118> PMID: 22455463
189. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunol Rev*. 2018; 281(1):8–27. Epub 2017/12/17. <https://doi.org/10.1111/imr.12621> PMID: 29247995; PubMed Central PMCID: PMC5756628.
190. Fahey E, Doyle SL. IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis. *Front Immunol*. 2019; 10:1426. Epub 20190625. <https://doi.org/10.3389/fimmu.2019.01426> PMID: 31293586; PubMed Central PMCID: PMC6603210.
191. Laird DW, Lampe PD. Therapeutic strategies targeting connexins. *Nat Rev Drug Discov*. 2018; 17(12):905–21. Epub 20181012. <https://doi.org/10.1038/nrd.2018.138> PMID: 30310236; PubMed Central PMCID: PMC6461534.
192. Delvaeye T, Vandenaabeele P, Bultynck G, Leybaert L, Krysko DV. Therapeutic Targeting of Connexin Channels: New Views and Challenges. *Trends Mol Med*. 2018; 24(12):1036–53. Epub 20181110. <https://doi.org/10.1016/j.molmed.2018.10.005> PMID: 30424929.
193. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012; 22(9):1775–89. <https://doi.org/10.1101/gr.132159.111> PMID: 22955988; PubMed Central PMCID: PMC3431493.
194. Fang Y, Wang J, Wu F, Song Y, Zhao S, Zhang Q. Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge. *Oncotarget*. 2017; 8(28):46090–103. <https://doi.org/10.18632/oncotarget.17552> PMID: 28545023; PubMed Central PMCID: PMC5542252.

195. Pelechano V, Steinmetz LM. Gene regulation by antisense transcription. *Nat Rev Genet.* 2013; 14(12):880–93. Epub 20131112. <https://doi.org/10.1038/nrg3594> PMID: 24217315.
196. MacDonald KP, Le Texier L, Zhang P, Morris H, Kuns RD, Lineburg KE, et al. Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10. *J Immunol.* 2014; 192(7):3180–9. Epub 20140228. <https://doi.org/10.4049/jimmunol.1302315> PMID: 24585878; PubMed Central PMCID: PMC4018243.
197. Dyer DP, Salanga CL, Johns SC, Valdambri E, Fuster MM, Milner CM, et al. The Anti-inflammatory Protein TSG-6 Regulates Chemokine Function by Inhibiting Chemokine/Glycosaminoglycan Interactions. *Journal of Biological Chemistry.* 2016; 291(24):12627–40. <https://doi.org/10.1074/jbc.M116.720953> PMID: 27044744
198. Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AEI, et al. TSG-6 Inhibits Neutrophil Migration via Direct Interaction with the Chemokine CXCL8. *The Journal of Immunology.* 2014; 192(5):2177–85. <https://doi.org/10.4049/jimmunol.1300194> PMID: 24501198
199. Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. *European Journal of Immunology.* 2003; 33(2):465–73. <https://doi.org/10.1002/immu.200310022> PMID: 12645945
200. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. *Annu Rev Immunol.* 2005; 23:337–66. <https://doi.org/10.1146/annurev.immunol.23.021704.115756> PMID: 15771574.
201. Smith DF, Galkina E, Ley K, Huo Y. GRO family chemokines are specialized for monocyte arrest from flow. *Am J Physiol Heart Circ Physiol.* 2005; 289(5):H1976–84. Epub 20050603. <https://doi.org/10.1152/ajpheart.00153.2005> PMID: 15937099.
202. Ahuja SK, Murphy PM. The CXC Chemokines Growth-regulated Oncogene (GRO) α , GRO β , GRO γ , Neutrophil-activating Peptide-2, and Epithelial Cell-derived Neutrophil-activating Peptide-78 Are Potent Agonists for the Type B, but Not the Type A, Human Interleukin-8 Receptor. *Journal of Biological Chemistry.* 1996; 271(34):20545–50. <https://doi.org/10.1074/jbc.271.34.20545> PMID: 8702798
203. Rudack C, Maune S, Eble J, Schroeder J-M. The Primary Role in Biologic Activity of the Neutrophil Chemokines IL-8 and GRO- α in Cultured Nasal Epithelial Cells. *Journal of Interferon & Cytokine Research.* 2003; 23(2):113–23. <https://doi.org/10.1089/107999003321455507> PMID: 12744776
204. Metzemaekers M, Gouwy M, Proost P. Neutrophil chemoattractant receptors in health and disease: double-edged swords. *Cellular & Molecular Immunology.* 2020; 17(5):433–50. <https://doi.org/10.1038/s41423-020-0412-0> PMID: 32238918
205. Zaja-Milatovic S, Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. *Histol Histopathol.* 2008; 23(11):1399–407. <https://doi.org/10.14670/HH-23.1399> PMID: 18785122; PubMed Central PMCID: PMC3140405.
206. Al-Alwan LA, Chang Y, Bagloli CJ, Risse P-A, Halayko AJ, Martin JG, et al. Autocrine-regulated airway smooth muscle cell migration is dependent on IL-17-induced growth-related oncogenes. *Journal of Allergy and Clinical Immunology.* 2012; 130(4):977–85.e6. <https://doi.org/10.1016/j.jaci.2012.04.042> PMID: 22698519
207. Chen C-L, Wang Y, Huang C-Y, Zhou Z-Q, Zhao J-J, Zhang X-F, et al. IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. *Oncimmunology.* 2017; 7(1). <https://doi.org/10.1080/2162402X.2017.1373234> PMID: 29296528
208. Doni A, Stravalaci M, Inforzato A, Magrini E, Mantovani A, Garlanda C, et al. The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer. *Front Immunol.* 2019; 10:712. Epub 20190404. <https://doi.org/10.3389/fimmu.2019.00712> PMID: 31019517; PubMed Central PMCID: PMC6459138.
209. Porte R, Davoudian S, Asgari F, Parente R, Mantovani A, Garlanda C, et al. The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis. *Front Immunol.* 2019; 10:794. Epub 20190412. <https://doi.org/10.3389/fimmu.2019.00794> PMID: 31031772; PubMed Central PMCID: PMC6473065.
210. Lee YT, Gong M, Chau A, Wong WT, Bazoukis G, Wong SH, et al. Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis. *J Infect.* 2018; 76(1):1–10. Epub 20171123. <https://doi.org/10.1016/j.jinf.2017.10.016> PMID: 29174966.